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ABSTRACT 
Hematopoietic stem cells (HSCs) reside in bone marrow (BM) microenvironment / niche to 
self-renew and generate all types of mature blood cells in postnatal life. This process is called 
hematopoiesis. Normal hematopoiesis is tightly regulated by both intrinsic signaling in HSCs 
and extrinsic signals from BM niche. Despite the involvement of BM niche in normal and 
malignant hematopoiesis has been reported, how different BM cellular niche contribute to 
leukemia progression and how leukemia cells affect their BM niche remain largely unknown.  
The overall aim of this thesis was to determine the roles of BM niche cells in the 
regulation of different myeloid malignancies, and understand the underlying mechanisms. In 
study I, by taking advantage of Sipa1-/- mouse model, we revealed that the loss of Sipa1 in 
mice led to BM niche alterations before the onset of MDS/MPN, and confirmed that the loss 
of Sipa1 in BM niche, but not in hematopoietic cells led to the MDS/MPN. Moreover, we 
detected abnormal inflammatory cytokines and growth factors in the BM stromal cells of the 
disease-free young adult Sipa1-/- mice, which could contribute to the pathogenesis of the 
MDS/MPN in aged Sipa1-/- mice. This study provides evidence for BM niche-induced 
MDS/MPN and the underlying molecular and cellular mechanisms. 
Given the distinct pathogenesis of different types of myeloid malignancies, we further 
investigated the contributions of BM niche to AML progression using MLL-AF9+ AML 
mouse model in study II. We detected alterations of BM niche cells in symptomatic AML 
mice, and confirmed similar alterations of BM stromal cells in the NSG mice engrafted with 
primary patient AML cells. Furthermore, BM niche cells in the AML mice produced altered 
growth factors, cytokines, and matrix proteins. Dynamic BM niche cell analysis and gene 
expression assay revealed that the BM niche alterations correlated with AML burden. We 
next functionally determined the roles of BM MSCs marked by Ebf2 expression in AML 
progression. We demonstrated that the Ebf2+ cells participated in AML BM niche formation. 
Notably, the depletion of Ebf2+ cells accelerated AML development in mice, indicating the 
suppressive roles of native BM niche to AML development. This study indicated that AML 
cells educated normal BM niche into a reinforcing AML BM niche contributing to AML 
progression.  
In study III, we found that BM MSCs altered their phenotype with reduced SCA1 
expression in non-adherent culture, emphasizing culture-related alterations of BM MSC 
immunophenotype. In study IV, by using LTC-IC assay and single cell PCR, we revealed 
diverse expressions of leukotriene signaling molecules and minor effects of ALOX5 and 
CYSLT1 antagonists on CML LSC growth, particularly in the presence of BM stromal cells 
in vitro. 
All together, we phenotypically, molecularly, and functionally characterized leukemic 
BM niche and determined the niche contributions to different myeloid malignancies. 
Targeting on BM niche factors or restore BM niche components might be new therapeutic 
strategies for these myeloid malignancies.   
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1 Introduction 
1.1 Hematopoiesis and HSC niche 
Normal hematopoiesis takes place in a series of various hematopoietic organs from the 
embryo stage to adult. Aorta-gonad-mesonephros, yolk sac, placenta, fetal liver, and spleen 
are involved in hematopoiesis during prenatal development, whereas bone marrow (BM) is 
the main organ for hematopoiesis after birth (Mikkola and Orkin, 2006). The concept of the 
BM hematopoietic stem cell (HSC) niche, a specialized BM microenvironment, was first 
proposed by Schofield with a view that the BM niche is critical for normal hematopoiesis 
(Schofield, 1978). The BM niche cells could secrete cytokines, growth factors, and matrix 
proteins, as well as mediate cell-cell interactions to regulate HSCs quiescence, proliferation, 
self-renewal, and differentiations. 
1.1.1 Normal hematopoietic cell hierarchy  
Under steady state, hematopoietic lineage cells, such as erythrocytes (red blood cells), 
platelets,  granulocytes, monocytes, and lymphocytes, are differentiated from HSCs in BM 
and released into the blood circulation after maturation. These blood cells play their specific 
roles in oxygen delivery, stopping bleeding, and defense against pathogens, maintaining a 
homeostasis of our bodies. 
Erythrocytes are hemoglobin-rich nucleus-free cells, working as the principal oxygen 
carriers to deliver oxygen throughout the body. Erythrocytes express Glycophorins A 
(CD235) in human (Merryweather-Clarke et al., 2011), and TER119 in mice (Koulnis et al., 
2011). They develop from reticulocytes and are phagocytized by macrophages after a life 
span of around 120 days. Similar to erythrocytes, platelets are also nucleus-free blood cells. 
Platelets are tiny cytoplasmic fragments generated from megakaryocytes, and play a critical 
role in hemostasis via adhering and aggregating to damaged vessel walls, followed by the 
activation of coagulation cascades.  
Granulocytes, including neutrophils, basophils, and eosinophils, are specific white 
blood cells with granules in their cytoplasm. They belong to the cells involved in the innate 
immune system, and defense against pathogen-mediated infections and inflammations. 
Mature granulocytes usually have multi-lobed nuclei and express CD11B and Gr1 on their 
cell surface. Monocytes are bigger than granulocytes and also express the cell surface marker 
CD11B but not Gr1. They can differentiate into macrophages, and defense against pathogen 
invasions together with granulocytes. Both granulocytes and monocytes are originally 
differentiated from BM HSCs, followed by common myeloid progenitors (CMPs) and 
granulocyte-macrophage progenitors (GMPs).   
Lymphocytes are composed of natural killer (NK) cells, B cells, and T cells with a 
relatively long lifespan (possibly up to several years in human) compared with other mature 
white blood cells. NK cells of C57BL/6 or NZB strain can be recognized with the cell surface 
marker NK1.1 (Stenstrom et al., 2005), whereas human NK cells express CD56. NK cells 
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join in innate immune response and induce apoptosis of infected cells. Mature B cells express 
CD19 as their cell surface marker. T cells express CD3 and can be subdivided into CD4+ 
helper T cells, and CD8+ cytotoxic T cells based on the different antigen expression on their 
cell surface after positive and negative selections in thymus. B cells and T cells participate in 
adaptive immunity to defend against antigens and pathogens through antibody- or cell-
mediated immune reactions.  
HSCs, the precursors of all mature blood cells located at the top of hematopoietic 
hierarchy, replenish downstream lineage cells and maintain hematopoietic homeostasis 
(Figure 1). In mouse, HSPCs express CD45, CD117 (c-KIT), and stem cell antigen 1 (SCA1) 
(Adolfsson et al., 2001) and are devoid of lineage markers (Lin), including TER119, CD11B, 
Gr1, CD3, CD4, CD8, CD19, and NK1.1. Therefore, BM HSPCs reside in Lin-SCA1+c-KIT+ 
cells (LSKs). HSPCs can be subdivided into long-term HSCs (LT-HSCs) with a phenotype of 
LSKFlt3-CD34-CD150+, short-term HSCs (ST-HSCs) as LSKFlt3-CD34+, and lymphoid-
primed multi-potential progenitors (LMPP) as LSKFlt3highCD34+ (Adolfsson et al., 2001; 
Christensen and Weissman, 2001; Kiel et al., 2005; Yang et al., 2005). Hematopoietic 
progenitor cells (HPCs) lack the SCA1 expression (LSK-). With the combinations of the 
markers of CD16/32 and CD34, HPCs are further divided into GMPs, CMPs, and 
megakaryocyte-erythrocyte progenitors (MEPs), presenting the phenotypes of LSK-
CD16/32+CD34+, LSK-CD16/32-CD34+, and LSK-CD16/32-CD34-, respectively. MEP may 
also be differentiated directly from HSCs (Pronk et al., 2007). CMPs give rise to GMPs and 
MEPs, and generate down-streams of granulocyte/monocyte and megakaryocyte/erythrocyte 
lineages (Akashi et al., 2000)  
 
Figure 1. Developmental hierarchy of murine hematopoietic cells. LT-HSCs give rise to 
hematopoietic progenitors and mature hematopoietic cells as described above.  
LT-HSC 
ST-HSC 
MPP 
CMP 
CLP 
MEP GMP 
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1.1.2 Regulations of hematopoiesis by BM microenvironment 
HSCs are located in the specific BM niche during postnatal life to self-renew and produce 
progenies. The anatomic architectures of the bone from the outer layer to the inside of this 
special cavity are periosteum (a membrane of connective tissue), cortical bone (hard bone), 
trabecular bone (spongy bone), and central marrow. Hematopoietic cells share this bone 
cavity together with other cells, such as osteoblasts, osteoclasts, macrophages, adipocytes, 
perivascular cells, mesenchymal stem cells, and endothelial cells. The communications 
among these different cells are mediated through various cytokines, growth factors, matrix 
proteins, and cell-cell adhesions. All these factors have been demonstrated to be HSC niche 
component as they are co-localized with HSCs and have the functional effects on HSC self-
renewal and differentiation (Scadden, 2006). 
1.1.2.1 The anatomic location of HSCs in bone marrow  
A few of the HSCs can migrate through the endothelial cells of vessels, circulate in the blood, 
and travel to other hematopoietic organs or come back home (BM) after circulation (Wright 
et al., 2001). Under such complicated trafficking inside and outside BM niche, the location of 
quiescent HSCs and more activated HSCs inside the BM are investigated.  
By using SLAM family markers, many mouse HSCs labeled as 
CD150+CD244+CD48- or CD150+CD48-CD41- (LT-HSC) are found located adjacent to 
sinusoidal vessels, and some HSCs are found in the endosteum area (Kiel et al., 2007; Kiel et 
al., 2005). However, ex vivo image tracing indicates that HSCs (labeled by GFP expression) 
are located in the endosteum region of bones in the mice after irradiation, and most of them 
are detected in the trabecular area (Xie et al., 2009). Furthermore, HSCs express calcium-
sensing receptors, and are located in calcium-rich endosteum (Adams et al., 2006). 
Additionally,  several studies reveal the existence of HSCs at both sinusoidal area and 
endosteum area (Lo Celso et al., 2009; Nilsson et al., 2001; Sugiyama et al., 2006). 
Transplanted HSCs are found to locate in the area that were rich in CXCL12 expressing cells 
(CAR cells) (Sipkins et al., 2005), and these CAR cells are found either close to endosteum 
area or around sinusoidal vessels in BM (Lo Celso et al., 2009; Sugiyama et al., 2006). 
However, the HSCs located in the osteoblast niche of the endosteal region are more quiescent 
than that in the vascular niche (Kunisaki et al., 2013; Lo Celso et al., 2009; Nilsson et al., 
2001).  
1.1.2.2 BM cellular niche in the regulation of HSCs  
 Osteoblasts  1.1.2.2.1
Osteoblasts, the precursors of osteocytes, account for a very small amount (around 5%) 
within total bone cells (Capulli et al., 2014). Together with osteoclasts, osteoblasts participate 
in bone constructions to and contribute to the maintenance of HSC niche (Capulli et al., 
2014). Through secreting collagen (e.g., collagen type 1) and non-collagen (such as 
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osteocalcin, osteopontin, and osteonectin) proteins, osteoblasts generate osteoid, which can 
be further mineralized to form osteocytes (Anderson, 2003).  
Osteoblasts are considered as one of important BM niche components in the 
regulation of hematopoiesis (Figure 2) (Calvi et al., 2003; Zhang et al., 2003). Cell-cell 
attachments are observed between LT-HSCs and osteoblasts at the surface of the trabecular 
area in mouse bone (Zhang et al., 2003). The number of HSCs is positively correlated with 
the number of osteoblasts (Zhang et al., 2003). Moreover, osteoblasts express Notch ligand, 
jagged 1, and can promote BM HSC expansions through activated Notch signaling (Calvi et 
al., 2003). Meanwhile, the Angiopoietin-1 (Ang-1) expressed by osteoblasts can bind to its 
receptor Tie2 on HSCs, and therefore maintains the BM HSCs at quiescent status (Arai et al., 
2004). Several BM niche factors are essential for hematopoiesis such as CXC chemokine 
ligand 12 (CXCL12) (Ding and Morrison, 2013; Greenbaum et al., 2013) and stem cell factor 
(SCF) (Czechowicz et al., 2007). CXCL12 is partially produced by osteoblasts, where the 
deletion of CXCL12 results in a mobilization of HSCs into circulation and reduced lymphoid 
progenitors (Greenbaum et al., 2013). On the other hand, osteoblasts support the lymphoid 
differentiation of HSCs via secreting interleukin (IL)-7 and cell-cell attachments (Zhu et al., 
2007) or activating Gsα signaling (Wu et al., 2008). All together, these studies indicate that 
osteoblasts contribute to the formation of BM HSC niche, thereby regulate the expansion and 
quiescence of BM HSCs, and balance myeloid and lymphoid differentiations during 
hematopoiesis.  
 
Figure 2. Osteoblasts control the BM niche size and regulate BM HSCs. Activated bone 
morphogenetic protein (BMP) signaling in osteoblasts increases the BM niche size followed by an 
expansion of BM HSCs. Activated parathyroid hormone (PTH) signaling enhances trabecular bone 
formations and elevates the level of Notch ligand, jagged 1, in osteoblasts. The activated Notch 
signaling in HSCs mediated by Notch and jagged 1 promotes BM HSC expansion. 
Several studies have shown that impaired osteoblasts induce abnormal hematopoiesis 
in BM using different mouse models (Figure 3) (Visnjic et al., 2001; Visnjic et al., 2004; Zhu 
et al., 2007). By using the Col2.3Δtk transgenic mouse model, it has been shown the declined 
bone mass along with a dramatic reduction of BM B-lymphoid progenitors, HSCs, and total 
BM cellularity (Visnjic et al., 2004; Zhu et al., 2007). Meanwhile, extramedullary 
Osteoblast 
HSCs 
Jagged1/Notch 
PTH 
BMP 
N-cadherin/β-catenin ? 
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hematopoiesis is noticed in the spleen and liver, which further confirms the impaired 
hematopoiesis in the mouse BM (Visnjic et al., 2004). Notably, the osteoblasts can be 
restored by withdrawing ganciclovir, followed by a recovery of BM hematopoiesis and 
reduced extramedullary hematopoiesis in the mice (Visnjic et al., 2004). Wnt signaling in BM 
niche is critical for maintaining BM HSC quiescence (Fleming et al., 2008; Schaniel et al., 
2011). The inactivated Wnt signaling (overexpression of Wnt paninhibitor Dkk1 or Wif1) in 
Col2.3-labeled osteoblasts leads to the enhanced cell cycling of HSCs at the expense of 
quiescent HSCs (Fleming et al., 2008; Schaniel et al., 2011). The importance of osteoblasts to 
the BM niche is not only restricted at the adult stage, but also at the fetal stage. After the 
depletion of osterix+ osteoblasts in the mice at fetal stage, the BM hematopoietic cells present 
enhanced proliferations (Coskun et al., 2014). Although these BM HSPCs can form CFU-Cs 
in vitro, they lose their BM homing capacity and can not engraft in the recipient BM after 
transplantation (Coskun et al., 2014). Together, these studies provide evidences of osteoblasts 
as an important element for regulating HSC maintenance.  
 
Figure 3. Abnormal BM hematopoiesis induced by impaired osteoblasts. The depletion of 
osteoblasts in Col2.3Δtk mice leads to reduced BM HSCs and B-lymphoid progenitors. The 
inactivated Wnt signaling in osteoblasts leads to a non-HSC autonomous decline of Wnt signaling in 
the HSCs, followed by the enhanced cell cycling of HSCs at the expense of the quiescent HSCs. 
 Endothelial cells  1.1.2.2.2
Endothelial cells are the surface layer of blood and lymphatic vessels, and directly in contact 
with blood or lymph. CD31 or Platelet/Endothelial Cell Adhesion Molecule 1 (PECAM-1) is 
a specific cell-surface membrane glycoprotein expressed on endothelial cells (Newman, 
1994). During embryonic development, endothelial cells and hematopoietic cells share the 
same precursor, so called hemangioblasts, which express tyrosine kinase receptor fetal liver 
✕!Wnt signaling 
Col2.3- 
HSC CMP CLP 
Normal  
BM HSC niche  
Myeloid ! 
Lymphoid "  
Osteoblasts Osteoblasts 
✕!
Col2.3Δtk- 
HSC  
quiescence "  
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kinase 1 (Flk1) (Choi et al., 1998; Shalaby et al., 1995). Mice without Flk1 at embryonic 
stage present dramatically declined hematopoiesis and vasculogenesis (Shalaby et al., 1995).  
The relationship between endothelial and hematopoietic cells is not simply the 
connection by their common precursor, but also the crucial regulation of hematopoiesis by 
endothelial cells. In vitro co-culture experiments have shown that endothelial cells can 
recover the colony forming capacity of irradiated HSCs (Chute et al., 2004; Muramoto et al., 
2006; Rafii et al., 1995). Endothelial cells can be isolated from different tissues, such as 
brain, heart, lung, liver, and kidney (Li et al., 2004). Among the diverse tissue-derived 
endothelial cells, the mouse/human brain-derived endothelial cells support hematopoiesis 
better than others through cell-cell adhesion and/or secreting soluble factors (Chute et al., 
2005; Chute et al., 2007; Davis et al., 1995; Rafii et al., 1994). These studies provide the in 
vitro evidence of endothelial cells in supporting HSCs, and arouse the curiosity of the in vivo 
roles of endothelial cells in the regulation of hematopoiesis. 
Using the approaches of real-time imaging, micro-CT, immunofluorescence imaging, 
and FACS, HSCs have been identified in vessel-enriched BM sinusoidal and endosteum areas 
(Ellis et al., 2011; Kiel et al., 2005; Xie et al., 2009). Taking advantage of various mouse 
models, the in vivo functions of endothelial cell in BM niche are further studied. The cytokine 
receptor subunit, gp130, is important in mediating the signals from the cytokines of IL6 
family (Taga and Kishimoto, 1997). The abandon of gp130 in both hematopoietic and 
endothelial cells leads to the loss of LT-HSCs and extramedullary hematopoiesis in mice, 
which can not be restored after transplantation of normal BM cells (Yao et al., 2005). 
However, HSCs deficient with gp130 generate normal hematopoiesis after transplanting into 
wild type mice, indicating the gp130 expression in the endothelial cells is critical for 
maintaining normal hematopoiesis (Figure 4) (Yao et al., 2005). In addition, SCF (or KITL) 
and CXCL12 are known as critical BM niche factors (Ara et al., 2003; Broudy, 1997; 
Czechowicz et al., 2007; Sugiyama et al., 2006; Tzeng et al., 2011). The specific depletion of 
SCF in endothelial cells in the “Tie2-cre;Scf fl/fl” mouse model leads to a loss of BM HSCs 
(Ding et al., 2012). The particular depletion of CXCL12 in endothelial cells in the “Tie2-
cre;Cxcl12 fl/fl” mice also results in reduced BM HSCs (Ding and Morrison, 2013). These 
studies suggest that endothelial cells are crucial BM cellular niche components for 
maintaining the BM HSC pool in vivo. 
Irradiation and chemotherapy lead to BM suppression with damaged hematopoietic 
cells and vessels, although the effects of chemotherapy and sub-lethally irradiation are less 
serious than that of lethally irradiation (Hooper et al., 2009). The regeneration of BM 
hematopoiesis after irradiation is regulated by BM endothelial cells (Hooper et al., 2009; 
Salter et al., 2009; Winkler et al., 2012). In vivo transplantation of endothelial progenitor cells 
enhanced mouse BM recovery after irradiation (Salter et al., 2009). However, the application 
of an anti-VE-cadherin antibody inhibits the vessel formation, and postpones the 
hematopoiesis and vasculogenesis in the mice (Salter et al., 2009). Apart from BM 
endothelial cells, the in vivo infusion of mouse brain-derived endothelial cells alone leads to a 
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better survival of the lethally irradiated mice than those infused with fetal blood-derived 
endothelial cells (Chute et al., 2007). Interestingly, the expression of an HSC related growth 
factor, pleiotrophin, is detected with a 25-fold higher expression in human brain-derived 
endothelial cells than in other tissue derived endothelial cells (Himburg et al., 2010). In vivo 
administration of pleiotrophin to the irradiated mice induce an enhanced BM hematopoiesis 
recovery through the Phosphoinositide 3 kinase (PI3K) signal pathway (Himburg et al., 
2010). 
A series of angiocrine factors produced by endothelial cells are involved in the 
vascular HSC niche regulation. E-selectin, an adhesion molecule, is specifically detected in 
BM endothelial cells and is essential for promoting HSC proliferations in mice (Winkler et 
al., 2012). In the Sele-/- mice, where the E-selectin is specifically depleted, the BM HSCs 
became more quiescent with an increased self-renewal capacity (Figure 4) (Winkler et al., 
2012). Interestingly, endothelial cells differentially regulate the HSCs/HPCs with different 
activities through different signal pathways (Figure 4). For example, endothelial cells 
maintain HSC self-renewal through the expression of Notch ligand (Butler et al., 2010) or 
increased angiocrine factors activated by Akt-mTOR signaling in the endothelial cells 
(Kobayashi et al., 2010); while endothelial cells with a co-activation of mitogen-activated 
protein kinases (MAPK) signaling and Akt-mTOR signaling maintain the HSPCs which are 
prone to lineage differentiation (Figure 4) (Kobayashi et al., 2010).  
 
Figure 4. Regulations of HSC quiescence and differentiation from Endothelial cells. The 
gp130 expression in endothelial cells is critical for maintaining LT-HSCs. The expression of E-
selectin in endothelial cells is essential for promoting HSC proliferations. Endothelial cells maintain 
HSC self-renewal through the expression of Notch ligand or increased angiocrine factors activated by 
Akt-mTOR signaling in the endothelial cells. Endothelial cells with a co-activation of MAPK 
signaling and Akt-mTOR signaling maintain the HSPCs which are prone to lineage differentiation. 
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Vascular endothelial growth factor (VEGF) is produced by various cell types, such as 
macrophages (Sunderkotter et al., 1994), platelets (Verheul et al., 1997), cancer cells 
(Boocock et al., 1995), and endothelial cells (Lee et al., 2007). VEGF binds to its receptor 
VEGFR1 and VEGFR2 that expressed in endothelial cells to promote angiogenesis 
(Carmeliet et al., 1996; Ferrara et al., 1996; Mustonen and Alitalo, 1995). Mice with only one 
allele of Vegf fail to survival due to the impaired vessel formation at the embryonic stage 
(Carmeliet et al., 1996; Ferrara et al., 1996). By using (VE-Cadherin-Cre x Vegflox/lox) mouse 
model, the depletion of Vegf in the endothelial cells leads to impaired angiogenesis, followed 
by an early death of the mice (Lee et al., 2007). However, the total level of VEGF protein is 
not much altered in these mice, indicating that the autocrine VEGF signaling in the 
endothelial cells results in the mouse death (Lee et al., 2007). Furthermore, endothelial cells 
express VEGFR2 and participate in the regeneration of irradiation-induced BM suppression 
in the mice. The conditional depletion of VEGFR2 has little effect on mouse hematopoiesis at 
steady state, but impairs BM hematopoietic reconstitution after irradiation (Hooper et al., 
2009). These studies do not show direct regulations of BM hematopoiesis by VEGF and 
VEGFR2, but might implying an indirectly effect on hematopoiesis mediated by endothelial 
cells and angiogenesis.  
It is believed that endothelial cells located at sinusoidal vessels and arteries play 
different roles in regulating hematopoiesis (Figure 5). With a common expression of 
VEGFR2 on the endothelial cells both sinusoids and arteries, sinusoidal endothelial cells are 
further marked by VEGFR3, whereas arterial endothelial cells are further labeled by SCA1 
(Hooper et al., 2009). The arteries are less permeable than sinusoids, located close to 
endosteum area, and present a low level of reactive oxygen species (ROS) for maintaining 
HSC quiescence (Itkin et al., 2016; Spencer et al., 2014). The sinusoids are mainly located at 
central marrow with a relatively higher ROS level, and form a special site for hematopoietic 
cells entering into circulation and coming back to BM (Itkin et al., 2016). Furthermore, the 
arterial endothelial cells are sheathed by Nerual/glial antigen 2 (NG2) pericytes which 
enhance HSC quiescence (Kunisaki et al., 2013). In addition, type H endothelial cells with 
high expressions of CD31 and Endomucin (CD31hiEmcnhi) are located in endosteum and 
trabecular area supporting osteogenesis (Kusumbe et al., 2014), which are indirectly involved 
in the hematopoiesis regulation. Take together, endothelial cells through direct cell-cell 
contact, cytokines, and angiocrine factors, as well as indirect pathways contribute to the BM 
vascular niche for maintaining hematopoiesis. 
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Figure 5. BM HSC vascular niche in endosteum area and central marrow. Sinusoidal 
endothelial cells are marked as VEGFR2+VEGFR3+, whereas arterial endothelial cells are labeled by 
VEGFR2+SCA1+. The arteries are located close to endosteum area, and present a low ROS level for 
maintaining HSC quiescence. The sinusoids are mainly located at central marrow with a relatively 
higher ROS level, and form a special site for hematopoietic cells trafficking. Arterial endothelial cells 
are sheathed by NG2 pericytes, which enhance HSC quiescence, whereas sinusoidal endothelial cells 
are surrounded by LepR+ cells. 
 Adipocytes  1.1.2.2.3
In adult human bone, BM hematopoietic cells are mainly located in metaphysis area, whereas 
BM adipocytes occupy most of space in diaphysis. These BM adipocytes, also known as 
yellow marrow, do not exist in diaphysis at newborn stage (Blebea et al., 2007). These 
adipocytes can be produced by BM stromal cells through activated leptin/lepR signaling (Yue 
et al., 2016). Perilipin, a lipid marker for  adipocytes (Greenberg et al., 1991), has been 
applied in immunohistochemistry staining for the identification of adipocytes in tissue. BM 
adipocytes are not simply occupying the bone cavity, but play crucial roles in the regulation 
of hematopoiesis. 
It has been shown that adipocytes cannot maintain the quiescence of HSCs, but 
promote HSC differentiation in co-cultivation (Corre et al., 2004). The cell-cell interactions 
between adipocytes and HSPCs can up-regulate the expression of neuropilin-1 on the 
adipocytes, leading to a reduction of granulocyte colony-stimulating factor (G-CSF) and a 
resultant inhibition of granulopoiesis (Belaid-Choucair et al., 2008). These studies indicate a 
negative regulation of hematopoiesis by BM adipocytes. 
In mice, BM HSCs have been shown to mainly locate in the adipocyte-free thoracic 
vertebrae, whereas a small number of HSCs locate in the caudal vertebrae where contains 
abundant of adipocytes (Naveiras et al., 2009). By using a fatless transgenic mouse model, it 
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has been shown an enhanced engraftment of HSCs in the fatless mouse BM along with an 
increased trabecular bone formation after BM transplantation (Moitra et al., 1998; Naveiras et 
al., 2009). Similarly, the inhibition of adipogenesis also increases HSC engraftment in 
irradiated mouse BM (Naveiras et al., 2009). Together, these studies suggest that adipocytes 
are an important BM niche component and negatively regulate the hematopoiesis in the BM.  
 Megakaryocytes  1.1.2.2.4
Megakaryocytes are hematopoietic lineage cells, which are identified as Lin-cKit+Sca1-
CD150+CD41+ in mouse BM (Nakorn et al., 2003; Pronk et al., 2007). In addition to the 
production of platelets, megakaryocytes can also regulate HSC activities. Platelet factor-4 
(PF-4), a member of the CXC chemokine family (CXCL4) (Slungaard, 2005), is mainly 
synthesized and stored in megakaryocytes, and released into BM together with platelets 
(Lasagni et al., 2007; Slungaard, 2005). PF-4 released by megakaryocytes maintains HSC 
quiescence through the inhibition of IL8-induced HSC activation and the enhanced adhesion 
of human HSCs to stromal cells (Dudek et al., 2003). Additionally, megakaryocytes have 
been shown to promote the proliferation of HSCs through insulin-like growth factor 1 (IGF-
1) signaling (Heazlewood et al., 2013) (Figure 6).  
Megakaryocytes attach to the vascular cells of the BM sinusoids (Avecilla et al., 
2004; Junt et al., 2007) and are adjacent to HSCs (Bruns et al., 2014; Heazlewood et al., 
2013; Zhao et al., 2014). Thrombopoietin (THPO) has been known to be critical for the 
maintenance of HSCs (Qian et al., 2007; Yoshihara et al., 2007). It has been found that the 
depletion of megakaryocytes in mice leads to a reduction of THPO in BM, followed by a 
mobilization of HSCs into circulation (Nakamura-Ishizu et al., 2014). Moreover, 
megakaryocytes can keep the quiescence of  BM HSCs through the production of CXCL4 
(Bruns et al., 2014). In addition, megakaryocyte-mediated transforming growth factor β 1 
(TGFβ1) signaling is also known to be critical for maintaining HSC quiescence (Zhao et al., 
2014). Mice with the depletion of megakaryocytes present a reduction of TGFβ1 in the BM, 
followed by a proliferation of BM HSCs (Zhao et al., 2014). A similar phenomenon is 
observed in the TGFβ1 knockout mice, where the quiescence of the HSCs can be restored 
after the treatment of TGFβ1 (Zhao et al., 2014). Together, these studies suggest that 
megakaryocytes are a critical BM cellular niche component and participate in the 
maintenance of BM HSC quiescence (Figure 6).  
However, under stress conditions, such as irradiation or chemotherapy, where BM 
hematopoietic cells and niche are damaged, megakaryocytes have been shown to actively 
support the hematopoiesis. It have been found that megakaryocytes migrate to the endosteal 
niche by activated THPO signaling to assist osteogenesis in irradiated mouse (Olson et al., 
2013). Furthermore, megakaryocytes promote the regeneration of endosteal osteoblasts in the 
irradiated mice by producing platelet-derived growth factor-BB (PDGF-BB) (Olson et al., 
2013). The interruption of THPO signaling by blocking THPO receptor (c-MPL) on 
megakaryocytes can reduce the engraftment of HSCs in the BM; while the application of 
THPO improves the BM hematopoiesis in the irradiated mice (Olson et al., 2013). Another 
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cytokine, fibroblast growth factor1 (FGF1), mainly produced by megakaryocytes, has been 
shown to support HSPC expansion in vitro (Faloon et al., 2000). Under chemotherapy-
induced stress condition, megakaryocytes can accelerate the proliferation of BM HSCs 
through the activated FGF1 signaling, which overwhelms the TGFβ1 signaling-induced 
inhibition of HSCs (Zhao et al., 2014; Zhao et al., 2012). All together, these studies suggest 
that megakaryocytes play critical roles in maintaining of BM HSC quiescence under 
homeostatic condition, and promoting the recovery of BM HSC niche under stress condition 
(Figure 6).  
 
Figure 6. Regulations of HSCs by Megakaryocytes under the steady state and stress 
condition. At steady state, megakaryocytes maintain HSC quiescence through CXCL4 and TGF-β1 
signal pathways, and promote HSC expansion through IGF-1 signaling. THPO preserves HSC 
quiescence at steady state and assists the migration of megakaryocytes to the endosteal niche to 
support HSC niche regeneration in irradiated mice. Megakaryocytes can produce PDGF-BB and FGF-
1 to facilitate the recovery of the BM HSC niche under stress conditions.   
 Mesenchymal stem cells (MSCs) 1.1.2.2.5
1.1.2.2.5.1 Criteria of defining MSCs  
The concept of BM HSC niche was proposed by Schofield in 1978. Prockop later confirmed 
that BM mesenchymal stromal cells could regenerate non-hematopoietic tissue for wound 
healing (Prockop, 1997). These mesenchymal stromal cells are selected by the plastic 
adherence in cultivation, and are further used for tissue regenerations in vivo. The ambiguous 
“MSCs” is the acronym for both mesenchymal stromal cells and mesenchymal stem cells. 
However, not all the adherent stromal cells present stem cell characteristics, including self-
renewal and multi-lineage differentiations (Horwitz and Keating, 2000). According to the 
standard from the International Society for Cellular Therapy (ISCT), “MSCs” only refers to 
the multipotent mesenchymal stromal cells with stem cell characteristics (Horwitz et al., 
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2005). Four minimal criteria of the definition of human mesenchymal stromal cells have been 
suggested (Dominici et al., 2006). First, MSCs are adherent stromal cells obtained from the 
standard culture selection. Second, MSCs express mesenchymal stem cell markers, such as 
CD150, CD90, and CD73. Third, MSCs do not express any hematopoietic markers, including 
CD45, CD14, CD34, CD11b, CD19, CD79α, and HLA-DR molecules. Finally, MSCs 
possess multi-lineage differentiation capacities, including adipogenic, osteogenic, and 
chondrogenic differentiations in vitro.  
1.1.2.2.5.2 Cell surface markers of human BM MSCs 
Due to the heterogeneity of MSCs, several cell surface markers have been applied to better 
identify the BM MSCs. The low affinity nerve growth factor receptor, also known as CD271, 
expresses in human BM stromal cells (Cattoretti et al., 1993). These CD271+ stromal cells 
mingle with hematopoietic cells, attach to the surface of sinusoids, and form a supportive 
scaffold for the BM cells (Cattoretti et al., 1993). The colony forming ability of the CD271+ 
stromal cells has been confirmed by colony-forming unit fibroblast (CFU-F) assay with a 
frequency of 1584 out of 1 million input cells, whereas no colony is detected in CD271- 
fraction (Quirici et al., 2002). Moreover, CD271+ stromal cells possess multi-lineage 
differentiation potentials, which can generate adipocytes, osteoblasts, and chondrocytes in 
vitro (Jones et al., 2006). In addition, CD271+ stromal cells express fatty acid binding protein 
4 (FABP4), SP7, CXCL12, and angiopoietin like 1 (ANGPTL1), suggesting the multi-potency 
and HSC supportive potentials of CD271+ stromal cells in vivo (Churchman et al., 2012). 
Together, these evidences indicate that CD271 is a surface marker for human MSCs. 
Given the fact that not every CD271+ stromal cell possesses stem cell characteristics, 
other markers are applied to identify human MSCs. The STRO-1+glycophorin A- BM cells 
have been considered as MSCs due to their capacities of CFU-F and multi-lineage 
differentiation in vitro (Simmons and Torok-Storb, 1991). Furthermore, CD105 (Endoglin) 
(Barry et al., 1999), CD49a (Integrin α1) (Deschaseaux and Charbord, 2000), CD90 
(Thymocyte differentiation antigen 1, THY1) (Vogel et al., 2003), CD140B (Platelet-derived 
growth factor receptor beta, PDGFRB) (Vogel et al., 2003), CD166 (Stewart et al., 2003), 
CD63 (Zannettino et al., 2003), and  CD73 (Boiret et al., 2005) have been also identified as 
human MSC markers. In addition, MSCs express CD146 (melanoma cell adhesion molecule, 
MCAM), which partially overlaps with CD105, CD49a, CD63, CD90, and CD140B antigens 
(Sacchetti et al., 2007). These CD146+ cell clones can self-renew after transplanting into 
NOD scid gamma (NSG) mice, and generate human bone and adventitial cells in the mice 
(Sacchetti et al., 2007). However, these markers label very heterogeneous cell populations, 
indicating their limitations in the identification of MSCs.  
To further purify BM MSCs, multicolor FACS has been employed. Combined with 
CD146 marker, the CD271+ MSCs are subdivided into CD271+CD146+ and CD271+CD146-
/low cells (Tormin et al., 2011). Both of them form CFU-Fs in vitro, but the CD271+CD146+ 
MSCs sit in the perivascular area, whereas the CD271+CD146-/low MSCs restrict in the 
endotheum region (Tormin et al., 2011). These results indicate that the phenotype of BM 
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MSCs varies between the endosteal niche and perivascular niche. The BM MSCs defined by 
the combination of CD271+CD90+CD106+ display a high CFU-F capacity with the frequency 
of one colony out of three input cells (Mabuchi et al., 2013). Moreover, the BM MSCs 
identified by CD45-CD31-CD71-CD146+CD105+nestin+ can grow as non-adherent 
mesenspheres, differentiate into multi-lineage, and promote HSC expansion (Isern et al., 
2013). In addition, CD140A+CD51+ stromal cells are enriched with MSCs in human fetal 
BM, which overlap with Nestin+ cells (Pinho et al., 2013). These human fetal 
CD140A+CD51+ MSCs can also form non-adherent mesenspheres, differentiate into 
adipocytes, osteoblasts, and chondrocytes, and support HSC expansion (Pinho et al., 2013) 
(Table 1).  
However, the phenotype of MSCs changes in different conditions, such as in vitro 
adhesive cultivation, the oxygen level of the culture condition, and growth factors in the 
culture media. First, freshly isolated MSCs do not express CD44, but acquire CD44 
expression when they are in an in-vitro cultivation (Qian et al., 2012). Second, the CD146 
expression of BM MSCs is higher in the normoxic culture condition than the hypoxic 
condition (Tormin et al., 2011). Third, CD271+ MSCs cultured in the basic fibroblast growth 
factor (bFGF) free media display the higher expression of CD271 than those cultured in the 
media containing bFGF (Quirici et al., 2002).  
Table 1.    Identified MSC markers of human BM. 
MSC markers 
(Human) 
Positive 
CD271, CD146, STRO1, CD49a, CD90, 
CD140B, CD105, CD166, CD63, and CD73 
Negative CD44 
Combination 
(Within CD45-CD235-CD31-) 
Tissue Reference 
CD271+CD146+ Adult BM Tormin et al., 2011 
CD271+CD90+CD106+ Adult BM Mabuchi et al., 2013 
CD71-CD146+CD105+Nestin+ Adult BM Isern et al., 2013 
CD140A+CD51+ Fetal BM Pinho et al., 2013 
 
1.1.2.2.5.3 Cell surface markers of mouse BM MSCs 
Hematopoietic and mesenchymal lineages are two distinct BM cell populations, although 
they express many common cell surface markers, such as CD49e, CD105, Sca1, Tie-2, and 
CD34 (Koide et al., 2007). Based on combined hematopoietic lineage markers and several 
MSC markers, the phenotype and function of murine MSCs are further identified (Figure 7).  
BM CD140A+CD51+ stromal cells not only present human fetal BM MSCs, but also 
mouse MSCs (Pinho et al., 2013). Using a mouse model where Nestin+ cells are labeled by 
green fluorescent protein (GFP), about 75% of CD140A+CD51+ MSCs are Nestin+, whereas 
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around 60% of total Nestin+ cells are CD140A+CD51+ (Pinho et al., 2013). These BM 
CD140A+CD51+ MSCs can form CFU-Fs and non-adherent mesenspheres, self-renew, and 
differentiate into adipocytes, osteoblasts, and chondrocytes in vitro (Pinho et al., 2013). 
Importantly, HSC niche genes, such as Scf, Cxcl12, vascular cell adhesion protein 1 
(Vcam1), Angpt1, and osteopontin (Opn), are highly expressed in the BM CD140A+CD51+ 
MSCs, indicating the HSC supportive function of the CD140A+CD51+ MSCs (Pinho et al., 
2013). Another combination of CD140A and Sca1 marks mouse BM MSCs as CD45-
TER119-CD31-CD140A+Sca1+ (Morikawa et al., 2009a; Morikawa et al., 2009b). The 
CD140A+Sca1+ MSCs have a high colony forming capacity with the frequency of 1 colony 
out of 40 input cells (Morikawa et al., 2009a). Compared with CD140A/Sca1 single positive 
and double negative stromal cells, the CD140A+Sca1+ MSCs exhibit much stronger multi-
lineage differentiation potentials in vitro (Morikawa et al., 2009a). HSC niche factors, such as 
Angpt1 and Cxcl12, are highly expressed in the CD140A+Sca1+ MSCs, which can support 
HSC reconstitutions in lethally irradiated mice (Morikawa et al., 2009a). These results 
suggest that CD140A is a specific mouse MSC marker, and that the combination of CD140A 
and CD51 or Sca1 can better characterize mouse MSCs.  
Apart from these combinations of MSC positive marker, it is worth mentioning a 
negative marker enriched for MSCs, CD44, which does not express on freshly isolated MSCs 
(Qian et al., 2012). Notably, CFU-Fs are enriched in the CD44- stromal cells, but not in the 
CD44+ stromal cells (Qian et al., 2012). Accordantly, the MSC markers of CD140A, CD51, 
and Sca1 are only detected in the CD44- stromal cells (Qian et al., 2012). Moreover, CD44- 
stromal cells exhibit much higher expression of niche associated genes than CD44+ stromal 
cells, such as Nestin, collagen type I alpha 1 (Col1a1), Angptl1, insulin-like growth factor 1 
(Igf1), Fibromodulin (Fmod), and nephroblastoma overexpressed (Nov) (Qian et al., 2012). 
This study suggested that naïve MSCs do not express CD44 antigen, and CD44 can be 
applied as a negative marker for the MSC enrichment.  
Other stromal cell markers, such as CD105 and CD140B, are also tested for 
identifying MSCs, but the labeled cells are very heterogeneous and restricted to mesenchymal 
lineages. For example, CD105-expressing stromal cells are restricted to an osteo-lineage-
biased MSC population in mouse BM (Chan et al., 2013). CD140B is expressed in culture-
selected MSCs and freshly isolated non-hematopoietic mouse cells, indicating CD140B is a 
potential marker for mesenchymal lineage cells (Koide et al., 2007).  
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Figure 7. Phenotypic and functional identification of mouse BM MSCs. Naïve mouse BM 
MSCs do not express the hematopoietic marker CD45 or TER119, and are negative for CD31 and 
CD44, but positive for CD51, CD140A, and Sca1. MSCs can form CFU-Fs in vitro and differentiate 
into adipocytes, osteoblasts, and chondrocytes. 
1.1.2.2.5.4 BM MSCs/MSPCs defined by using genetic mouse models 
By taking the advantage of genetically modified mouse models, MSCs labeled by specific 
gene markers and can be tracked for their locations and functions in vivo. Here I summarize 
several identified MSCs using different genetic mouse models (Figure 8).  
v LepR+ MSCs  
Leptin Receptor (LepR) labeled cells attach to sinusoids and arteries and are identified as 
perivascular cells with MSC characteristics in adult mice (Zhou et al., 2014). LepR+ MSCs 
are a rare cell population in mouse BM with an average frequency of 0.22% of BM CD45-
TER119-CD31- stromal cells (Zhou et al., 2014). Phenotypically, more than 98% LepR+ 
MSCs express CD140A or CD51 (Zhou et al., 2014), and 70% LepR+ MSCs express both 
CD140A and CD51 (Pinho et al., 2013). Up to 94% of the in vitro colonies formed by BM 
mononuclear cells are contributed by LepR+ MSCs, indicating the high CFU-F capacity of 
the LepR+ MSCs (Zhou et al., 2014). Moreover, LepR+ MSCs are quiescent at steady state, 
but give rise to adipocytes, osteoblasts, and chondrocytes in vivo after irradiation or bone 
injury (Zhou et al., 2014). However, LepR+ MSCs lose LepR expression after differentiating 
into mature osteolineages, suggesting that LepR+ MSCs generate LepR- lineages in vivo 
(Mizoguchi et al., 2014). Additionally LepR+ MSCs express the BM niche maintenance 
genes, such as Scf and CXCL12 (Zhou et al., 2014). The specific deletion of Cxcl12 from 
LepR+ MSCs leads to the mobilization of BM HSPCs into the spleen and blood (Ding and 
Morrison, 2013). The conditional depletion of SCF from LepR+ MSCs leads to a dramatic 
reduction of HSCs in mouse BM, suggesting the crucial role of SCF from LepR+ MSCs in 
maintaining HSCs (Ding et al., 2012). Together, these studies suggest that LepR+ MSCs are 
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not only the major source for different BM niche cells, but are also important for the 
maintenance of HSCs in BM niche. 
v Ebf2+ MSCs 
Early B cell factor 2 (Ebf2) is a transcription factor of the Ebf family (Garel et al., 1997). In 
contrast to the expression of Ebf1 in B lymphocytes, Ebf2 is not detectable in the 
hematopoietic cells of adult mice (Kieslinger et al., 2010; Qian et al., 2013). However, Ebf2 
is expressed in osteoprogenitors (Kieslinger et al., 2005; Kieslinger et al., 2010), 
adipoprogenitiors (Rajakumari et al., 2013; Wang et al., 2014), neurons (Giacomini et al., 
2011; Wang et al., 2004; Yang et al., 2015) and BM niche cells (Qian et al., 2013). By taking 
advantages of Tg(Ebf2-GFP) transgenic mouse model, Ebf2 is identified as a BM MSC 
marker in mice (Qian et al., 2013). BM Ebf2+ MSCs are mainly located in the endosteal area 
and possess multi-lineage differentiation capacities in vivo and in vitro (Qian et al., 2013). 
Phenotypically, Ebf2+ MSCs express MSC-related cell surface markers, such as SCA1, 
CD51, CD140A, and CD90, but do not express CD44 (Qian et al., 2012). Notably, Ebf2+ 
MSCs exhibit a high capacity of CFU-Fs with a frequency of 1 colony out of 6 input cells, 
which is higher than that of CD140A+SCA1+ MSCs (1 out of 40 input cells) (Morikawa et al., 
2009a; Qian et al., 2013). Furthermore, BM niche genes are enriched in the BM Ebf2+ MSCs, 
such as runt-related transcription factor 2 (Runx2), Angptl1, Nov, Fmod, Nestin, and N-
cadherin, indicating HSC supportive functions of the Ebf2+ MSCs (Qian et al., 2013). 
Additionally, the mice without Ebf2 (Ebf2-/-) show reduced HSPC number and declined 
lymphopoiesis (Kieslinger et al., 2010). Nevertheless, the BM cells of the Ebf2-/- mice 
generate normal hematopoiesis after transplanting into a normal BM niche, indicating the 
niche-dependent hematopoietic disorder in the Ebf2-/- mice (Kieslinger et al., 2010). On the 
other hand, Ebf2-/- stromal cells impair the function of normal HSCs in co-culture, implying a 
critical role of Ebf2 expression in the BM niche (Kieslinger et al., 2010). All together, these 
studies suggest that Ebf2+ MSCs are fulfill the MSC criteria and are essential niche cells for 
maintaining normal hematopoiesis in mouse BM.  
v Nestin+ MSCs 
By using the mouse model Tg(Nestin-GFP) for lineage tracing, Nesin+ cells are identified as 
the neural stem/progenitor cells in mouse brain (Mignone et al., 2004). In mouse BM, Nestin+ 
cells mark a specific cell population displaying MSC characteristics and locate closely to 
HSCs and vessels (Mendez-Ferrer et al., 2010). These Nestin+ MSCs can form CFU-Fs and 
non-adherent mesenspheres and differentiate into adipocytes, chondrocytes, and osteoblasts 
in vitro (Mendez-Ferrer et al., 2010). Based on the expression levels of GFP, Nestin+ MSCs 
are divided into Nestin+ GFPhigh MSCs and Nestin+ GFPdim MSCs (Kunisaki et al., 2013). 
Most of Nestin+ MSCs are labeled by dim GFP and close to sinusoids, whereas the Nestin+ 
GFPhigh MSCs are much rare in numbers and locate in the periarteriolar area (Kunisaki et al., 
2013). Several BM niche genes for maintaining HSC homeostasis are detected in Nestin+ 
MSCs, such as Cxcl12, Kitl, Angpt1, Il7, Vcam1, and Spp1 (Mendez-Ferrer et al., 2010). The 
specific depletion of Nestin+ MSCs using the (Nes-cre ER2;iDTR) mouse model, leads to 
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reduced BM HSPCs and increased spleen HSPCs (Mendez-Ferrer et al., 2010). These studies 
indicate that Nestin+ MSCs are a critical BM cellular niche component for maintaining BM 
hematopoiesis.  
Although Cxcl12 is highly expressed in Nestin+ MSCs, the depletion of Cxcl12 from 
Nestin+ MSCs using “Nestin-Cre x Cxcl12fl/fl” mouse model has no effect on hematopoiesis 
(Balordi and Fishell, 2007; Ding and Morrison, 2013). Moreover, the depletion of Scf from 
Nestin+ MSCs does not affect hematopoiesis in the mouse BM, but reduces the HSC 
frequency in the mouse spleen (Ding et al., 2012). These studies indicate that CXCL12 and 
SCF from the Nestin+ MSCs are dispensable for the hematopoiesis in the mouse BM. 
However, SCF secreted by the Nestin+ MSCs may be important for the hematopoiesis in the 
mouse spleen.  
In one week postnatal mice, Nestin marks not only BM MSCs, but also other stromal 
cell types. More than 90% osteolineage cells labeled by osterix (Osx), Col1 (3.2kb), or 
osteocalcin (Ocn) express Nestin (Ono et al., 2014). Most of the Tie2+ endothelial cells and 
the majority of the LepR+ MSCs are also positive for Nestin (Ono et al., 2014). In addition, 
about 96% Nestin+ cells express NG2 in adult mice (Asada et al., 2017). These evidences 
suggest that postnatal Nestin+ cells are heterogeneous stromal populations, including 
osteoprogenitors, osteoblasts, endothelial cells, NG2 periarteriolar cells, and MSCs. 
v Prx1+ MSCs 
Paired related homeobox gene 1 (Prx1) expressing cells are heterogeneous mesenchymal 
stromal cells and are involved in limb formations (Logan et al., 2002). About 95% of Prx1+ 
cells express CD140A (Ding and Morrison, 2013), and around half of the PαS cells 
(CD140A+Sca1+ MSCs) are positive for Prx1 expression (Greenbaum et al., 2013). Prx1+ 
cells have a high CFU-F capacity with an average frequency of 1 colony out of 10 input cells, 
and can differentiate into adipocytes and osteoblasts in vitro (Greenbaum et al., 2013). These 
Prx1+ MSCs secrete CXCL12; and the conditional depletion of Cxcl12 from Prx1+ MSCs 
leads to the reduced HSCs and lymphoid progenitors in the mouse BM (Ding and Morrison, 
2013; Greenbaum et al., 2013). Furthermore, the depletion of LepR from Prx1+ MSCs results 
in an enhanced bone formation and declined adipocyte differentiation in mice (Yue et al., 
2016). Collectively, these studies suggest that Prx1+ MSCs are important for replenishing BM 
niche cells and maintaining HSC pools in the mouse BM.  
v Mx1+ MSCs 
Myxovirus resistance-1 (Mx1) expressing cells within the mouse BM stromal cells are also 
characterized as MSCs (Park et al., 2012). About half of the CD105+CD140A+ stromal cells 
express Mx1, indicating an MSC phenotype of the Mx1+ cells (Park et al., 2012). They can 
form CFU-Fs in vitro, with an average frequency of 1 colony out of 40 input cells (Park et al., 
2012). Although Mx1+ MSCs can differentiate into adipocytes, chondrocytes, and osteoblasts 
in vitro, they are restricted to osteolineages and contribute to bone fracture regenerations in 
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vivo (Park et al., 2012). Due to these features, mouse BM Mx1+ MSCs are considered as 
osteo-restricted progenitors in vivo, although they fully fit the criteria of MSCs in vitro.  
v Cxcl12+ MSPCs (CAR cells) 
The chemokine CXCL12 is also known as pre-B cell growth stimulating factor (PBSF) or 
stromal cell-derived factor 1 (SDF-1) (Nagasawa et al., 1996; Nagasawa et al., 1994). 
CXCL12 is produced by different BM stromal cells, such as MSCs, MPCs, endothelial cells, 
reticular cells, osteoblasts, and mature BM stromal cells (Sugiyama et al., 2006). CXCL12-
abundant reticular cells (CAR cells) refer to the BM stromal cells with a high CXCL12 
expression (Sugiyama et al., 2006). CAR cells are not embedded in the mineralized bone, but 
sporadically distributed in the BM cavity (Sugiyama et al., 2006). Phenotypically, BM CAR 
cells are positive for VCAM-1 (CD106), mostly positive for MSC marker CD51 and 
CD140A/B, low/negative for CD44, and undetectable for SCA1 (Omatsu et al., 2010). The 
freshly isolated BM CAR cells fail to form colonies in vitro, indicating that CAR cells have 
little self-renewal capacity (Omatsu et al., 2010). CAR cells express differentiation genes, 
such as Runx2, Osterix, and, peroxisome proliferator-activated receptor gamma (PPARγ), 
which are related to the osteogenic and aidpogenic differentiations in special culture media 
(Omatsu et al., 2010). Moreover, CAR cells involve in the maintenance of BM homeostasis 
through CXCL12-CXCR4 signaling and CAR cell-HSC adhesions (Sugiyama et al., 2006). 
In addition to the secretion of CXCL12, CAR cells also produce a high level of SCF (Omatsu 
et al., 2010), which is critical for lymphopoiesis and maintaining the BM HSC pool. These 
evidences indicated that the heterogeneous CAR cells contain a variety of BM stromal 
progenitors and mature stromal cells, and serve as the main source of CXCL12 and SCF in 
BM. 
v Grem1+ MSPCs 
Gremlin 1 (Grem1) can inhibit BMP signaling and is critical for new bone formation (Canalis 
et al., 2012; Khokha et al., 2003). Mouse BM Grem1+ cells are fully negative for 
hematopoietic markers, but partially positive for CD105, CD140A, Sca1, and low 
CD140A+SCA1+ (Worthley et al., 2015). The Grem1+ cells have a better self-renewal 
capacity than the Nestin+ MSCs, which is confirmed by the higher frequency of CFU-Fs of 
the Grem1+ cells (Worthley et al., 2015). However, the Grem1+ cells can differentiate into 
osteoblasts and chondrocytes in vitro, but can not generate adipocytes (Worthley et al., 2015). 
Furthermore, both endogenous and transplanted BM Grem1+ cells form new bones in vivo 
and contribute to the bone fracture healing (Worthley et al., 2015). Together, mouse BM 
Grem1+ cells are considered as an osteo-restricted stem and progenitors and involve in new 
bone formation in vivo. The roles of BM Grem1+ cells in the regulation of hematopoiesis are 
yet to be further investigated. 
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Figure 8. Relationships among the BM MSC/MSPC populations defined by using 
different genetic mouse models. CAR cells are highly express the chemokine CXCL12, and 
contain a variety of BM stromal progenitors and mature stromal cells. About 75% of CD140A+CD51+ 
MSCs are Nestin+, whereas around 60% of Nestin+ cells are CD140A+CD51+ (Pinho et al., 2013). 
About 70% LepR+ MSCs express both CD140A and CD51 (Pinho et al., 2013). About 95% of Prx1+ 
cells express CD140A (Ding and Morrison, 2013), and around half of the PαS cells (CD140A+Sca1+ 
MSCs) are positive for Prx1 expression (Greenbaum et al., 2013). About 44% of the 
CD105+CD140A+ stromal cells express Mx1 (Park et al., 2012). Grem1+ MSPCs do not express 
Nestin but are partially positive for CD140A (Worthley et al., 2015). Ebf2+ MSCs are fully positive 
for CD140A and CD51 (Qian et al., 2013). 
1.1.2.3 Essential BM HSC niche soluble factors for maintaining normal 
hematopoiesis 
v CXCL12 
CXCL12 has been shown to maintain BM HSC pools through CXCL12-CXCR4 signal 
pathway (Sugiyama et al., 2006). The universal depletion of CXCL12 leads to a proliferation 
of BM hematopoietic progenitors along with a reduction of BM LT-HSCs in mice (Tzeng et 
al., 2011). However, CXCL12 secreted by different BM stromal cells exhibits different 
effects on hematopoiesis (Ding and Morrison, 2013; Greenbaum et al., 2013). For example, 
the depletion of CXCL12 in Prx1+ MSCs leads to dramatic reductions of LT-HSCs and 
common lymphoid progenitors, along with a mobilization of HSPCs (Ding and Morrison, 
2013; Greenbaum et al., 2013). The depletion of CXCL12 in Tie2+ endothelial cells results in 
impaired BM HSCs with mild effect on other hematopoietic progenitors (Ding and Morrison, 
2013; Greenbaum et al., 2013). The depletion of CXCL12 in Osterix+ or Col2.3+ osteoblasts 
leads to reduced lymphoid progenitors (Ding and Morrison, 2013; Greenbaum et al., 2013). 
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Moreover, a mobilization of HPCs is found when CXCL12 is specifically removed from 
Osterix+ osteoblasts (Greenbaum et al., 2013). The conditional depletion of CXCL12 in 
NG2+ pericytes induces the mobilization of quiescent BM HSCs into circulation and results 
in a reduction of BM HSCs (Asada et al., 2017). However, the depletion of CXCL12 in 
LepR+ MSCs has little effect on the hematopoiesis in BM (Asada et al., 2017; Ding and 
Morrison, 2013). Additionally, no effect on BM hematopoiesis is found when CXCL12 is 
depleted in osteocalcin (Oc)+ mature osteoblasts or Nestin+ cells or Vav1+ hematopoietic cells 
(Ding and Morrison, 2013; Greenbaum et al., 2013). These evidences suggest that CXCL12 
produced by various BM cells differentially regulates BM hematopoiesis and that CXCL12 is 
a crucial BM niche factor (Table 2).  
Table 2. Effects of CXCL12 on BM hematopoiesis 
CXCL12 depletion 
in specific cells  Effects on BM hematopoiesis References 
Cxcl12 knock-out LT-HSCs ê, and ST-HSCs é  Tzeng et al., 2011 
Prx1-Cre 
LT-HSCs ê, CLPs ê 
Mobilizations of HSCs into circulation é 
Ding and Morrison, 2013; 
Greenbaum et al., 2013 
Tie2-Cre HSCs ê  Ding and Morrison, 2013; Greenbaum et al., 2013 
Osx-Cre 
Pre-pro B cells ê, CLP ê 
Mobilizations of HSCs into circulation é 
Greenbaum et al., 2013 
Col2.3-Cre Lymphoid progenitors ê Ding and Morrison, 2013 
NG2-Cre 
HSCs ê 
Mobilizations of HSCs into circulation é 
Asada et al., 2017 
Lepr-Cre No obvious effect  Ding and Morrison, 2013; Asada et al., 2017 
Oc-Cre No obvious effect Greenbaum et al., 2013 
Nestin-Cre No obvious effect  Ding and Morrison, 2013 
Vav1-Cre No obvious effect  Ding and Morrison, 2013 
 
v SCF 
SCF is also known as Kit ligand (Kitl) or Steel (Sl) factor, which binds c-Kit expressing 
HSPCs (Williams et al., 1990; Zsebo et al., 1990). Mice lacking membrane-bound SCF 
display impaired hematopoiesis, which can be restored after the transplantation of their BM 
cells into a normal BM niche (Barker, 1994, 1997). These studies indicate critical roles of 
membrane-bound SCF in the BM niche for maintaining the HSC pool. Nevertheless, the SCF 
secreted by different BM stromal cells differentially regulates HSCs. The conditional 
depletion of SCF in Tie2+ endothelial cells (Ding et al., 2012) or LepR+ MSCs (Asada et al., 
2017; Ding et al., 2012) or NG2+ pericytes (Asada et al., 2017) leads to a dramatic reduction 
of BM HSCs. However, the SCF secreted by Nestin+ cells, Col2.3+ osteoblasts, or Vav1+ 
hematopoietic cells is dispensable for BM hematopoiesis (Ding et al., 2012). Therefore, SCF 
secreted from vascular niche is essential for maintaining BM HSCs (Table 3).  
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Table 3. Effects of SCF on BM hematopoiesis  
SCF depletion in 
specific cells  Effects on BM hematopoiesis References 
Tie2-Cre Normal BM cellularity; LT-HSCs ê  Ding et al., 2012 
Lepr-Cre Normal BM cellularity; LT-HSCs ê Ding et al., 2012; Asada et al., 2017 
NG2-Cre Normal BM cellularity; LT-HSCs ê Asada et al., 2017 
Nestin-Cre No obvious effect  Ding et al., 2012 
Col2.3-Cre No obvious effect Ding et al., 2012 
Vav1-Cre No obvious effect  Ding et al., 2012 
v THPO  
THPO is mainly secreted by liver, kidney, and BM stromal cells (Ishikawa et al., 1998; 
McIntosh and Kaushansky, 2008; Sungaran et al., 1997). THPO binds to its receptor MPL 
which is expressed in LT-HSCs to inactivate the cell cycling of HSCs (Kimura et al., 1998; 
Qian et al., 2007; Yoshihara et al., 2007). Furthermore, the BM in-situ secretion of THPO is 
detected in osteoblasts at endosteal area, strengthening BM LT-HSC quiescence through the 
in-situ THPO/MPL signaling (Yoshihara et al., 2007). These evidences suggest that THPO is 
a critical BM niche factor to maintain HSC quiescence in adult.  
1.1.3 Other BM microenvironmental cells 
Sympathetic nerves have been shown to play a role in maintaining and restoring normal 
hematopoiesis by regulating soluble factors like CXCL12 (Lucas et al., 2013; Mendez-Ferrer 
et al., 2008). Schwann cells in BM contribute to the maintenance of HSC quiescence through 
the activating TGF-β/Smad signaling in HSCs (Yamazaki et al., 2011).  
In summary, HSCs reside in BM niche and are tightly regulated by direct cell-
interaction with BM niche cells or soluble factors secreted by the niche cells. Knowledge of 
cellular and molecular mechanisms underlying the BM niche regulation in normal 
hematopoiesis is fundamental for exploring the roles of different BM niche components in 
hematological malignancies. 
1.2 BM niche in myeloid malignancies 
In 1889, Dr. Paget formulated the famous “seed and soil” hypothesis to explain why 
metastases of breast cancer can spread to specific organs (Paget, 1989). In addition to cancer 
metastasis, the “seed and soil” hypothesis also suggests a dual cause of cancers, which can be 
induced either from the cancer cells (seed) and/or their environment (soil). Here, I summarize 
the recent evidence on BM niche contributions to myeloid malignancies, such as 
myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), and myelodysplastic 
syndrome (MDS), and describe the crosstalk between the leukemic cells (seed) and the BM 
niche (soil). 
 22 
1.2.1 BM niche contribution to MPN  
MPN are heterogeneous diseases characterized by at least one myeloid lineage with chronic 
clonal proliferation in BM. According to the 2016 World Health Organization (WHO) 
classification, MPN include chronic myeloid leukemia (CML) with BCR-ABL expression, 
and BCR-ABL- MPN, such as chronic neutrophilic leukemia (CNL), polycythemia vera 
(PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic 
leukemia, and unclassified MPN (Arber et al., 2016).  
1.2.1.1 Intrinsic regulation of CML 
CML is a clonal disease characterized by the appearance of the Philadelphia chromosome 
which is caused by the translocation of t(9;22)(q34;q11) (Groffen et al., 1984). This 
translocation results in the expression of the BCR-ABL oncogene, a constantly active tyrosine 
kinase (Groffen et al., 1984). Treatments with tyrosine kinase inhibitors (TKIs), such as 
imatinib, greatly improve the survivals of CML patients (Hochhaus et al., 2017). However, 
many patients do not respond to imatinib therapy, and some patients have to stop imatinib 
because of serious side-effects (Gambacorti-Passerini et al., 2011). Despite the increased use 
of new TKIs, such as dasatinib, nilotinib, radotinib, and bosutinib, many patients are still 
facing drug resistance, serious side-effects, and disease relapse, particularly after TKI 
discontinuation (Ongoren et al., 2017). Therefore, further understanding the underlying 
mechanisms of CML and searching for alternative drugs are in great need to improve patient 
outcomes.  
CML has been identified as a hematopoietic stem cell disease by using the BCR-ABL 
CML mouse model, (Schemionek et al., 2010). The mouse CML can be induced by BCR-
ABL+ LSK, but not by BCR-ABL+ LSK- progenitors or BCR-ABL+ mature granulocytes 
(Schemionek et al., 2010). Many signaling pathways including β-catenin, c-MYC and 
declined p53 are involved in the development of CML (Abraham et al., 2016; Eiring et al., 
2015). Alox5, coding for arachidonate 5-lipoxygenase (5-LO), has been demonstrated to be 
critical for leukemic stem cell survival in the CML mice (Chen et al., 2009). The deficiency 
of Alox5 or the application of a 5-LO inhibitor impairs the LSCs and prolongs the CML 
mouse survival (Chen et al., 2009). However, our recent study using CML patient samples 
suggests that the leukotriene inhibitors acting on 5-LO and cysteinyl leukotriene receptor-1 
play minor role in human LSC survival in vitro (Dolinska et al., 2017). More studies with a 
bigger patient cohort with CML are necessary to further address the therapeutic effects of 
leukotriene inhibition on CML LSC persistence. 
1.2.1.2 Remodeling effects of leukemic cells on the BM niche 
The involvement of the BM niche in leukemia development has drawn much attention to 
characterization of leukemic BM niche and search for alternative treatments targeting BM 
niche. Two classic MPN mouse models are used to study the roles of the BM niche in the 
regulation of MPN. One is the CML mouse model induced by BCR-ABL expression in 
hematopoietic cells. The other mouse model is induced by the mutated gene janus kinase 2 
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(JAK2(V617F)), which is detected in most of BCR-ABL negative MPN patients (Baxter et 
al., 2005; Kralovics et al., 2005). 
 BM niche remodeling in CML 1.2.1.2.1
Mouse CML cells often induce an overproduction of BM osteoblast progenitor cells and 
promote myelofibrosis in the CML BM. The increase of osteoblasts is mediated by cell-cell 
attachments and an increase of the soluble factors including chemokine ligand 3 (CCL3) and 
THPO in the CML BM niche (Schepers et al., 2013). These CML osteoblast progenitor cells 
exhibit activated TGF-β, Notch, Wnt, and inflammatory signaling, which is involved in the 
process of myelofibrosis (Schepers et al., 2013). The gene expression of Cxcl12, Scf, and 
Angpt1 is reduced in the osteoblast progenitors of the CML mice, contributing to a decline of 
normal hematopoietic supportive function in vivo (Schepers et al., 2013). Together, these 
results indicate that the mouse CML cells gradually educate their BM niche into a leukemic 
niche to favor the LSC expansions (Schepers et al., 2013) (Figure 9).  
 
Figure 9. BM niche remodeling in CML. Mouse CML cells gradually educate their BM niche 
into a leukemic niche to favor the LSC expansions.  
 BM niche alterations in JAK2(V617F) MPN 1.2.1.2.2
BM niche contribution to MPN progression has also shown in the JAK2 mutated mouse 
model. Sympathetic signaling and BM Nestin+ MSPCs are reduced in MPN patients and 
JAK2(V617F) mutated MPN mice (Arranz et al., 2014). In the MPN mice, JAK2(V617F) 
mutated malignant hematopoietic cells induce the neuropathy and a decline of BM Nestin+ 
MSPCs in the BM via IL-1β production and impaired adrenergic signaling (Arranz et al., 
2014). Application of β3-adrenergic agonist or neuroprotective medicine can protect BM 
Nestin+ MSPCs from apoptosis, followed by a prevention of the MPN (Arranz et al., 2014). 
These data provide evidence for the niche disruption induced by the JAK2(V617F) mutated 
malignant cells, which may in turn facilitate the MPN progression (Figure 10A).  
The JAK2(V617F) mutation has been reported to be detected in the endothelial cells 
of MPN patients, indicating the potential involvement of endothelial cells in MPN 
development (Rosti et al., 2013; Teofili et al., 2011). Using the (Tie2-Cre; JAK2(V617F)) 
CCL3 ! 
THPO ! 
Impaired 
osteoblasts 
myelofibrosis 
CML 
Scf " 
Cxcl12 " 
Angpt1 " 
HSC 
TGFβ, Notch, Wnt, and Inflammatory 
 signaling ! 
Osteoblast 
Scf 
Cxcl12 
Angpt1 
HSC 
Normal BM niche CML BM niche 
 24 
mouse model, the JAK2(V617F) mutation can be specifically activated in the endothelial 
cells. The mutated endothelial cells support JAK2(V617F) HSCs better than wild type 
endothelial cells (Zhan et al., 2017). Compared to wild type endothelial cells, the 
JAK2(V617F) mutated endothelial cells exhibit increased CXCL12, SCF, and THPO/MPL 
signaling to promote the expansion of JAK2(V617F) HSCs in vivo (Zhan et al., 2017). These 
results indicate that the JAK2(V617F) mutated endothelial cells promote the growth of the 
JAK2(V617F) mutated HSCs and may contribute to the MPN progression (Figure 10B).  
 
Figure 10. Roles of the BM niche in the JAK2(V617F) mutation-induced MPN. (A) The 
sympathetic nervous system is damaged by the JAK2(V617F) mutated HSCs, which facilitates the 
MPN progression. (B) The JAK2(V617F) mutated endothelial cells promote the growth of the 
JAK2(V617F) mutated HSCs and accelerate to the MPN progression. 
1.2.1.3 Instructive roles of BM niche in the pathogenesis of MPN  
 Gene deficiencies in BM niche can induce MPN-like disease 1.2.1.3.1
There are increasing evidence showing critical roles of the BM niche in the MPN 
pathogenesis (Figure 11). Mice with Retinoic acid receptor γ (RARγ) deficiency present the 
MPN-like phenotype, including increased myeloid progenitors and mature myeloid cells, BM 
hypercellularity, and myeloid cell infiltration in other tissues (Walkley et al., 2007a). 
However, transplantation experiments suggest that the phenotype of the mice is not caused by 
the loss of RARγ in the hematopoietic cells, but in the BM niche cells (Walkley et al., 2007a). 
TNF signaling is increased in the RARγ deficient BM niche, and mediates the pathogenesis 
of the disease (Figure 11A) (Walkley et al., 2007a). Moreover, the RARγ deficient BM niche 
is absolutely required to maintain the MPN phenotype in secondary recipients, indicating 
critical roles of BM niche in the initiation of the MPN (Walkley et al., 2007a). In addition, 
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retinoblastoma protein (RB) deficiency in mouse BM cells leads to increased myelopoiesis in 
Mx-cre;pRbfl/fl mice (Walkley et al., 2007b). The Rb deficient mice exhibit increased myeloid 
cells, cKit+ HSPCs, and total mononuclear cells in the BM (Walkley et al., 2007b). 
Nevertheless, the depletion of RB in the myelo-restricted hematopoietic cells or in the BM 
niche alone cannot induce the phenotype (Walkley et al., 2007b). This study indicates the 
importance of the BM niche homeostasis in maintaining normal hematopoiesis and MPN 
pathogenesis.  
 Ptpn11E76K activating mutation in BM MSPCs induces MPN 1.2.1.3.2
PTPN11 mutation is often detected in patients with MPN. The patients with PTPN11 
activating mutation are prone to develop leukemia, especially juvenile myelomonocytic 
leukaemia (JMML), a childhood MPN (Roberts et al., 2013). The activation of Ptpn11E76K in 
Prx1+ MSCs, or Lepr+ MSCs, or Nestin+ MSCs, or Osx1+ osteoprogenitors alone induces the 
MPN (Dong et al., 2016). However, Ocn+ mature osteoblasts or VE-Cadherin+ endothelial 
cells with the activated Ptpn11E76K mutation fail to induce the MPN (Dong et al., 2016), 
suggesting the critical role of Ptpn11 signaling in mesenchymal progenitor cells for the MPN 
initiation. The Ptpn11E76K mutated MPN cells produce IL-1β, whereas the Ptpn11E76K 
mutated BM MSPCs produce a higher level of CCL3, which may promote the MPN 
progression, since CCL3 antagonists can restore the MPN phenotype in these mice (Dong et 
al., 2016). This study provides novel evidence for the critical role of BM niche in the 
initiation and progression of the MPN (Figure 11B). 
 
Figure 11. Instructive roles of the BM niche to MPN pathogenesis. (A) The loss of RARγ in 
the BM niche drives the MPN in mice. (B) The Ptpn11E76K mutation in mouse BM hematopoietic cells 
or MSPCs leads to the MPN development through the productions of IL-1β and CCL3, respectively. 
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 SIPA1 deficiency in MPN development  1.2.1.3.3
Signal-induced proliferation-associated gene-1 (SIPA1) is a specific Rap1 GTPase-activating 
protein (Rap1GAP), which inactivates Rap1 signaling to regulate cell proliferation, adhesion, 
and survival (Figure 12) (Jin et al., 2006; Kometani et al., 2004; Kurachi et al., 1997; Minato 
and Hattori, 2009). SIPA1 expression is detected in lymphocytes and LSKs (Hattori et al., 
1995; Ishida et al., 2003). Abnormal expressions of SIPA1 are related to the pathogenesis of 
several solid cancers, such as cervical cancer (Brooks et al., 2010), breast cancer (Ugenskiene 
et al., 2016; Yi and Li, 2014; Zhang et al., 2015), and prostate cancer (Park et al., 2005). 
SIPA1 point mutations are detected in JMML patients with unclear pathological functions 
(Yoshida et al., 2008), and in AML patients with the CEBPA mutation (Dolnik et al., 2012).  
The in vivo function of SIPA1 in hematopoiesis has been demonstrated in a Sipa1 
gene deleted mice (Sipa1-/-) (Ishida et al., 2003). Sipa1-/- mice have normal hematopoiesis and 
develop normally until five months of age. However, most of the Sipa1-/- mice develop age-
dependent myeloid disorders with very heterogeneous phenotypes, such as CML-like MPN, 
MDS-like, and undefined hematological disorders with blast cells of diverse lineages (Ishida 
et al., 2003). Endogenous SIPA1 is reduced in the HPCs with an overexpression of BCR-
ABL, followed by enhanced Rap1 signaling in the cells (Kometani et al., 2006). Interestingly, 
Sipa1 is not only expressed by hematopoietic cells, but also by different BM stromal cells, 
such as MSCs, MPCs, endothelial cells, and mature stromal cells (indicated in attached Paper 
I), open the possibility of the effect of SIPA1 expression in BM niche on the development of 
the MPN. 
 
Figure 12. SIPA1 signaling and the Sipa1-/- mouse model. (A) SIPA1 is a specific Rap1GAP, 
which inactivates Rap1 signaling to regulate cell proliferation, adhesion, and survival. (B) Sipa1-/- 
mice have normal hematopoiesis and develop normally until five months of age. Most of the Sipa1-/- 
mice develop myeloid disorders with very heterogeneous phenotypes at 16 months of age. 
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1.2.2 BM niche involvement in MDS and AML development 
1.2.2.1 AML-induced alterations of BM niche  
It has been shown that the MLL-AF9+ AML mice exhibit increased numbers of endothelial 
cells, MSPCs (Lin-CD31-CD140A+CD51+), Nestin+ MSPCs, and LepR+ MSCs, but reduced 
NG2+ pericytes in the BM (Hanoun et al., 2014). In a xenograft NSG mouse model, human 
AML cells are engrafted in a normal human bone biopsy implanted in the NSG mouse and 
shift the normal niche into an osteogenic niche (Battula et al., 2017). In addition, AML cells 
induce the lipolysis of adipocytes to generate fatty acids which can be consumed by the AML 
cells for their survival (Shafat et al., 2017). The BM stromal cells of newly diagnosed AML 
patients present reduced gene expressions of ANGPT1, KITL, and THPO, indicating an 
impaired hematopoiesis supportive function of the AML stromal cells (Desbourdes et al., 
2017). Together, these studies indicate that AML cells alter the compositions and functions of 
the BM niche to form a leukemic niche favoring their own growth.  
1.2.2.2 Dysfunctional BM HSC niche induces leukemic transformation 
The deficient BM niche can also alter normal hematopoiesis and induce leukemia (Figure 
13). The conditional depletion of Dicer1 in the osterix+ osteoprogenitors leads to MDS in the 
mice and some of the MDS mice develop secondary AML (Raaijmakers et al., 2010). A 
reduced expression of the Shwachman-Diamond-Bodian syndrome (Sbds) gene is detected in 
the osteoprogenitors after the depletion of Dicer1, which is related to the MDS and AML in 
the mice (Raaijmakers et al., 2010). The mice deficient in Sbds in osteoprogenitors develop 
MDS formation, which is mediated by the activated p53-S100A8/9-TLR4 inflammatory 
signaling in BM (Zambetti et al., 2016). Similarly, an enhanced inflammatory signaling has 
been detected in human BM stromal cells with low risk MDS, indicating the involvement of 
inflammatory signaling in leukemia development (Chen et al., 2016).  
It has been shown that the intrinsic Wnt/β-catenin signaling in the AML cells is 
critical for the expansion of leukemic stem cells (Wang et al., 2010). However, the abnormal 
Wnt/β-catenin signaling in the osteoblasts also contributes to AML progression. Using the 
Ctnnb1CAosb mouse model, the constitutive activation of a β-catenin mutant in the osteoblasts 
leads to AML. This leukemic transformation is promoted by the activated Notch signaling in 
HSCs, which is attributed to the increased expression of the Notch ligand jagged1 in the 
osteoblasts along with the increased Notch receptors in the HSPCs (Kode et al., 2014). 
Moreover, FoxO1 expression in the osteoblasts enhances the activated β-catenin signaling 
with an up-regulated jagged1 expression in the osteoblasts and instigates the AML 
progression (Kode et al., 2016; Sykes et al., 2011). In turn, by using the Apcdel/+ mouse 
model, it has been shown that the reduced β-catenin in the mouse BM niche prevents the 
MDS progression (Stoddart et al., 2017). Collectively, these studies suggested that the 
genetically impaired BM niche can induce MDS and/or AML in mice.  
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Figure 13 Impaired BM HSC niche induce MDS and/or AML. The conditional depletion of 
Dicer1 in the osterix+ osteoprogenitors leads to MDS in the mice and some of the MDS mice develop 
secondary AML (upper panel). The constitutive activation of a β-catenin mutant in the osteoblasts 
leads to the AML in the Ctnnb1CAosb mice (lower panel). 
1.2.2.3 BM niche protection to AML cell survival during chemotherapy 
BM stromal cells express CXCL12, which can bind to its receptor CXCR4 that is expressed 
in hematopoietic cells to regulate HSC activities, such as homing and maintaining HSC 
quiescence (Sugiyama et al., 2006). Endogenous CXCR4 is also detected in AML cells, and 
the application of CXCL12 cytokine in culture promotes the survival of the AML cells 
(Tavor et al., 2004). A CXCR4 antagonist has previously been developed to hinder human 
immunodeficiency virus-1 (HIV-1) activities, and is now applied for leukemia treatments 
through inhibition of CXCL12/CXCR4 signaling (Oberlin et al., 1996). The application of 
the CXCR4 antagonist leads to impaired homing, engraftment, and infiltration of AML cells 
in mice, inhibits AML cell growth and prolongs mouse survival (Nervi et al., 2009; Tavor et 
al., 2004; Zeng et al., 2009). It has been shown that the BM-derived stromal cell line HS-5 
protects AML cells from chemotherapy-induced apoptosis under co-culture condition 
(Garrido et al., 2001). This protection is mediated by the CXCL12/CXCR4 signaling and the 
activated mammalian target of rapamycin (mTOR) signaling between the stromal cells and 
AML cells (Braun et al., 2016). In addition, AML cells bind to BM stromal cells through the 
very late antigen-4 (VLA-4) expressed in leukemic cells and fibronectin receptors in stromal 
cells to escape from chemotherapy-induced apoptosis (Bendall et al., 1993; Bendall et al., 
1998; Matsunaga et al., 2003). The combination treatment with anti-VLA-4 antibody and 
cytosine arabinoside accelerates the apoptosis of the AML cells and diminishes the minimal 
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residual disease of AML (Matsunaga et al., 2003). Together, these studies indicate that the 
protective roles of BM stromal cells for AML cells during chemotherapy, and that targeting 
the interactions may be promising for the treatment of leukemia. 
1.2.3 Distinct regulations of leukemic cells by BM niche in different types of 
leukemia 
Previous studies have indicated that the distinct roles of the BM niche in leukemia 
progression in different types of leukemia (Krause et al., 2013). The continuous activation of 
PTH signaling in BM osteoblasts leads to a reduction of BCR-ABL+ CML cells, but 
promotes the MLL-AF9+ AML cell expansion in the mice (Krause et al., 2013). The opposite 
outcomes in the CML and AML mice indicate the distinct role of the disease-specialized BM 
niche in leukemia progressions (Krause et al., 2013).  
1.3 Significance of studies on BM HSC niche 
HSCs reside in the BM niche to self-renew and generate mature blood cells in postnatal life. 
The BM niche regulates HSC activities through secreting cytokines, growth factors, and 
matrix proteins, as well as cell-cell interactions. Studies have shown that LSCs can remodel 
the normal BM niche into a leukemic niche, which in turn the abnormal BM niche can also 
induce leukemia and promote leukemia progression in mice. Evidence has shown that 
interfering with these interactions can restore or attenuate disease development in mice. 
Better understanding of the interactions between LSCs and their BM niche may help to 
design alternative therapies targeting BM niche for the treatment of leukemia. 
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2 Aim of the Thesis 
The overall aim of the thesis is to understand the roles of BM mesenchymal stem and 
progenitor cells in the regulation of myeloid malignancies, including MPN and AML. 
• Study I 
To determine whether BM microenvironment contributes to the pathogenesis of MPN by 
using a Sipa1 deficient mouse model.  
• Study II 
To identify whether and how BM stromal cells contribute to AML niche formation and the 
dynamic role of the BM niche cells in AML development by using a transplantation-induced 
MLL-AF9 AML mouse model. 
• Study III 
To study the effect of different cultivation methods on the immunophenotype, gene 
expression, and proliferation of mouse MSCs. 
• Study IV 
To examine the expressions of leukotriene signaling molecules of CML leukemic stem and 
progenitor cells by single cell assays and the effects of leukotriene inhibitors on the survival 
of CML LSCs using pharmaceutical inhibitors targeting ALOX5 or cysteinyl leukotriene 
receptor 1 in vitro.  
 
  31 
3 Methodological Approaches 
All animal experiments included in this thesis have been approved by Karolinska Institutet 
ethic committee with the ethical number of S40-14, and patient sample collections have been 
approved with permission of 2012/4:10, 2013/3:1, and 2013/1248-31/4 at Stockholm. Here I 
describe the main methods applied to the studies. 
3.1 Mouse MSC FACS isolation and analysis 
MSCs isolation technique has been evolved for several decades from previously plastic 
culture selection to nowadays prospective isolation of primary MSCs. Plastic culture selected 
MSCs are obtained by seeding bulk BM cells into culture and washing away non-adherent 
cells after several passages (Prockop, 1997). This procedure is easy to perform to get 
abundant MSCs, however, it presents several disadvantages as our increased knowledge 
about MSCs. First, hematopoietic cells can not be completely removed in plastic culture even 
after several passages, leads to a residual hematopoietic cells mixed with the culture-selected 
MSCs. Second, plastic culture can alter the phenotype of primary MSCs, which is indicated 
by the fact that primary human and mouse MSCs do not express CD44, but acquire CD44 
expression after culture (Qian et al., 2012). Third, culture selected cells are very 
heterogeneous cell population, and not all culture adherent stromal cells possess the MSC 
characteristics, including self-renewal, expressing MSC marker, and multi-lineage 
differentiation capacities (Horwitz and Keating, 2000). Fourth, most of MSCs are located at 
endosteum area and can not be easily obtained through simply crushing the bones, but 
through treating the bone with collagenase II and trypsin-EDTA. Therefore, in paper I, II, 
and III, we performed the mouse BM MSC isolation following our standard isolation 
protocol tested by Qian (Qian et al., 2012) to obtain freshly sorted MSCs for our studies.  
To make sure with the qualities of freshly isolated MSC, several details need to be 
pay attention to. First, high serum (10% to 20%) in the isolation media is required to keep 
good viabilities of the sorted MSCs. Second, low temperature (on ice or 4°C) can also keep 
MSCs with a good viability. Third, mixing well of bone fragments during incubation with 
collagenase and trypsin-EDTA is important, which helps with the MSC dissociation from 
bones. Fourth, sheep anti-rat IgG Dynalbeads®, which has been designed to isolate cell 
populations through binding to rat-anti-mouse antibodies, needs to be prewashed before hand 
to remove the possible ingredient which might be harmful to MSCs. Finally, fluorescence-
activated cell sorting (FACS) need to be performed as soon as possible to preserve functional 
MSCs. FACS is a laser based cell sorter that can separate heterogeneous cells one by one into 
1 to 4 enriched cell populations according to the activated fluorescence on the cells (Julius et 
al., 1972). After staining the cells with specific fluorescence conjugated antibodies, samples 
are acquired by sorter FACSAriaIII (BD), and data are presented in FACSDiva (BD) 
software, where each dot represented one cell from the sample. The cell sorting is gated based 
on fluorescent minus one (FMO) and the sorted cells are freshly collected for colony assay or 
gene expression assay.  
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3.2 Human MSC FACS isolation 
Concerning about the disadvantages of plastic culture selected MSCs, we also perform 
freshly isolation of patient BM MSC following our standard isolation protocol (Qian et al., 
2012). To collect BM mononuclear cells from patient samples, we apply Lymphoprep (Axis 
Sield) to samples with density centrifugation. Nevertheless, given the fact the density of BM 
stromal cells are heavier than that of hematopoietic mononuclear cells, we collect both the 
interface mononuclear cells, and those in the liquid between the interface mononuclear layer 
and red blood cell sediments. In addition, we use negative markers for sorting human MSCs, 
including non-hematopoietic (CD45-CD235-), non-endothelial (CD31-), and CD44-, due to 
the fact that primary MSCs are enriched in CD44- fraction (Qian et al., 2012). However, we 
also include MSC positive markers, such as CD146 and CD271, to confirm our CD44- 
MSCs. 
3.3 CFU-F assay 
BM MSCs have the capacity to form fibroblast-like colony (> 50 cells) in culture, whereas 
mature stromal cells can not survive in culture and some stromal progenitor cells can only 
form clusters (< 50 cells). Therefore, CFU-F assay is a method for assessing functional MSCs 
in vitro (Friedenstein et al., 1970). In the attached papers, we performed CFU-F assay 
following our standard protocol (Qian et al., 2012) to address two questions. First, to evaluate 
whether the functionally defined MSC were altered, we seeded unfractionated mouse BM 
cells containing those collected from bone fragment dissociation for CFU-F assay. Second, to 
identify CFU-F capacity of pure MSCs from normal and leukemic mice, we seeded freshly 
sorted mouse BM MSCs (Lin-CD45-CD44-CD51+SCA1+) for CFU-F assay.  
3.4 In vitro co-culture and CFU-C assay 
In vitro co-culture hematopoietic stem and progenitor cells (HSPCs) and BM stromal cells 
can be applied to evaluate the hematopoietic supportive function of BM stromal cells 
(Nakamura et al., 2010). In paper I, to avoid the effects of long time co-culture induced 
declines of CFU-C capacity of HSPCs, we co-cultured the freshly sorted LSKs with freshly 
sorted BM stromal cells for only 2.5 days. After co-culture, the effects from BM stromal cells 
on hematopoietic stem and progenitor cells were accessed by CFU-C assay. CFU-C assay is a 
classic colony assay based on the morphology of the formed colony to evaluate the 
differentiation capacity of HSPCs in semi-liquid media containing specific cytokines 
(Bradley and Metcalf, 1966). In this semi-liquid media, HSPCs are seeded at a low density to 
reach well separations from each other to form single cell colony. The unipotent HPCs are 
identified by the morphology of the colony containing single lineages, such as granulocytes 
(CFU-G), monocytes (CFU-M), and erythrocytes (CFU-E). The bipotent HPCs and multi-
potent HSPCs are identified by the morphology of CFU-GM and CFU-GME, respectively. 
However, the CFU-C assay also have its limitations. First, distinguishing the morphology of 
different colony requires substansive experience, we should score the colonies before they 
over-confluence and take counting error into consideration. Second, culture conditions, such 
as temperature and humidity, can also affect colony formations. Third, abnormal HSPCs 
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defected in responding to cytokine stimulation can not be evaluated by CFU-C assay 
(Metcalf, 1993).   
3.5 In vitro multi-lineage differentiation assay 
MSCs have capacities to differentiate into osteoblasts, adipocytes, and chondrocytes 
(Dominici et al., 2006). However, during pathogenesis of myeloid disease, the multi-lineage 
differentiation capacity can change (Battula et al., 2017; Hanoun et al., 2014). In attached 
paper I and II, we performed multi-lineage differentiation assays following our standard 
protocol (Qian et al., 2013) to evaluate the functional alterations of MSCs from the MPN or 
AML mice compared with that of normal mice. Mouse MSCs were freshly sorted and 
cultured in mouse complete Mesencult media (R&D or Stem Cell Techn.) for 7-10 days. The 
cells were then collected and cultured in differentiation induction media for osteoblast, 
adipocyte, and chondrocyte differentiations.  
The evaluation of osteoblast differentiation is based on newly formed calcium 
deposition, which bind to Alizarin Red S to form Alizarin Red S-calcium compound with a 
red color. This mineralization complex is further dissolved by acetic acid and quantified 
using plate reader at absorbance at 405 nm. Adipocyte differentiation is evaluated by the fat 
lipid formation in the cells. The fat lipid is recognized by its special morphology, however, 
the fat lipid can be easily dissolved during the process of histology staining such as 
hematoxylin and eosin (HE) staining. Therefore, we take advantage of Oil Red O, a fat 
soluble dye, which exhibits enhanced solubility in fat lipid than in the dye solvents, and stains 
the fat lipid with a red color. Unlike the osteoblast and adipocyte differentiations performed 
under normoxic condition, chondrocyte differentiation is performed under hypoxic condition 
(1% O2). Chondrocyte differentiation can be induced in monolayer culture, but can reach a 
better induction in pellet culture (3D culture) (Zhang et al., 2010). The chondrocyte 
differentiation is confirmed by Toluidine blue, which stains the specific matrix proteins in the 
differentiated chondrocyte cytoplasm with a purple color. 
3.6 Transplantation experiments 
BM transplantation is a procedure that replacing endogenous hematopoietic cells with newly 
donor cells. Irradiation is normally applied to the recipient mice to empty BM space for the 
transplantation of normal hematopoietic donor cells. Lethally irradiation can maximally clear 
up endogenous hematopoietic cells to reach a high level of donor engraftment, whereas 
sublethally irradiation can obtain a lower engraftment of donor cells with less harm for 
endogenous cells. However, transplantation of immortalized leukemic cells may not need to 
irradiate the recipient mice, since leukemic cells can compete with normal hematopoietic 
cells and occupy the space in BM with time. 
In paper I, we designed transplantation experiments to determine whether the 
development of the MPN was attributed to Sipa1 deficiency in the hematopoietic cells or the 
BM niche. Two doses of irradiation were applied before the transplantations to test our 
hypothesis. First, in order to maintain the physiological function of the recipient BM niche, 
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and meanwhile obtain reasonable donor cell engraftment, we performed sublethally 
irradiation (6 Gy) before transplantation. Second, to examine the donor hematopoietic activity 
in a clean BM niche without affection from endogenous hematopoietic cells, we applied 
lethally irradiation (9.5 Gy) to the recipient mice before transplantation. The CD45.1+ or 
CD45.2+ BM cells were enriched by MACS using CD45 microbeads. These transplantation 
experiments provided the possibility to determine whether normal hematopoietic cells could 
develop MPN in Sipa1-/- BM niche. On the other hand, the Sipa1-/- cells were transplanted 
into lethally irradiated CD45.1 Sipa1+/+ mice to test whether Sipa1-/- hematopoietic cells 
could develop MPN in a normal BM niche.  
In paper II, to study BM niche contributions on AML progression, we set up the 
AML mouse model by intravenous transplantation of the MLL-AF9 retrovirus transduced 
mouse BM KIT+ cells after clonally propagation in complete methylcellulose M3434 as 
reported (Somervaille and Cleary, 2006). No irradiation was performed to set up this AML 
mouse model. To study BM niche alterations, we transplanted MLL-AF9+ AML cells to wild 
type CD45.2 C57BL6J mice. To determine the involvement of Ebf2+ MSCs and their derived 
progenies in the AML development, MLL-AF9+ AML cells were transplanted into Ebf2-Egfp 
reporter mice and triple transgenic Tg (Ebf2-Egfp x Ebf2-CreER x Rosa26-loxpStoploxp-Tomato) 
mice, respectively. To further evaluate the critical roles of Ebf2+ MSCs in the AML 
development, MLL-AF9+ AML cells were transplanted into Tg (Ebf2-CreER x Rosa26-
loxpStoploxp-Dta) mice. Primary BM or PB mononuclear cells from AML patients were 
transplanted to sublethally irradiated (2.2 Gy) NSG mice through intra femoral injection to 
set up AML in immunosuppressive NSG mice. 
3.7 Analysis of hematopoietic cells after transplantation  
Analysis of blood reconstitution after transplantation is an essential method to check 
transplantation efficiency. In attached study I and II, to monitor hematopoietic changes, 
peripheral blood (PB) was collected from the tail vain in EDTA-coated tubes after 
transplantation, and was counted in an automated cell counter for blood components. The 
blood cell morphology was analyzed by blood smears and cytospins, which were stained by 
May-Grünwald-Giemsa. Flow cytometry analysis was performed to analyze hematopoietic 
lineage components in BM and blood based on specific antigen expression on different 
hematopoietic cells. Mature hematopoietic lineage cells include myeloid cells (CD11B+GR1+ 
and CD11B+GR1- monocytes), B cells (CD19+), T cells (CD4+ / CD8+ or CD3+) and NK cells 
(NK1.1+), which are derived from HSCs and HPCs in BM and spleen. Therefore, further 
estimate of the HSCs and HPCs compositions in BM and spleen is important to know the 
early alterations of hematopoiesis. 
3.8 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a quantitative immunoassay to test specific protein levels in liquid samples. It 
works as “sandwich” binding, where the 96-well plate is pre-coated with specific antibody for 
the test antigen, after exposure the specific antigen in the liquid samples to the plate for one 
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hour, the extra liquid is washed away. A specific enzyme-linked antibody is then added to 
bind to the test antigen in the 96-well plate. After another incubation followed by the removal 
of the extra enzyme-linked antibody, the stop solution is applied to each well and the color of 
absorbent could be measured under ELISA reader at 450 nm. The concentration of the testing 
antigen in the samples is further calculated based on standard curve. Due to the high 
sensitivity and specificity of ELISA assay, we used this technic to quantify the amount of 
THPO in mouse blood and BM as described in paper I. 
3.9 Quantitative RT-PCR and single cell RT-PCR 
PCR is a specific technique that can amplify the RNA transcripts of different tissues in vitro 
(Maheaswari et al., 2016). In attached paper I and II, to better understand the underlining 
mechanisms of BM niche in MPN and AML developments, we performed real-time 
quantitative PCR (Q-PCR) on freshly sorted BM niche cells, including MSCs, MPCs, CD51-
Sca1- stromal cells, and endothelial cells. Due to the very few MSCs (less than 5000 cells in 
total) obtained from BM samples, we used RNeasy Micro Kit (Qiagen) for RNA isolation. 
We chose Hprt/HPRT as the housekeeping gene for QPCR analysis due to its stable and 
uniform expression in the BM stromal cells of the control and experiment mice. In paper I 
and II, we performed Q-PCR using TaqMan probes, which contained a fluorophore in the 
oligonucleotide. During amplification, fluorophore is released from the oligonucleotide and 
activated with a fluorescence, which can be detected by Q-PCR equipment. Given the 
specific hybridization between target gene and probe, TaqMan Q-PCR is considered as a low 
background and very sensitive method for detecting gene expressions. In addition, we 
performed Q-PCR to monitor the alterations of Sca1 expression using SYBR Green I PCR kit 
in paper III. In paper IV, we applied single-cell RT-PCR as described (Qian et al., 2013) to 
detect BCR/ABL expression and genes involved in leukotriene signal pathways. 
3.10 RNA sequencing and data analysis 
RNA sequencing is a technique that provides a comprehensive gene expression profile of 
specific cell populations (Ingolia et al., 2012; Wang et al., 2009). Compared with microarray, 
RNA sequencing is more precise in transcriptome profiling including non-coding RNA in 
addition to coding RNA. RNA sequencing data can provide the information of new gene 
candidate to further identify their roles in pathogenesis of disease (Jabbari et al., 2012). In 
paper I, to further determine the molecular mechanisms involved in the pathogenesis of the 
MPN, we performed RNA sequencing to search for molecular alterations in different BM 
stromal cells from control and experiment mice. Due to the rare stromal population in BM, 
we extracted the RNA using RNeasy microkit. The cDNA library was prepared by using the 
Ovation® Ultralow Library Systems and subjected to 50 cycles of HiSeq 2000 or 76 cycles of 
NextSeq500 sequencing  generating 20-30 million reads/sample.  
All raw sequence reads available in FastQ format were mapped to the mouse genome 
(mm10) using Tophat2 combining with Bowtie2 (Kim et al., 2013; Langmead and Salzberg, 
2012). PCR duplicates were removed using samtools (Li et al., 2009) after reads mapping. 
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Next, raw reads mapped to each gene were calculated using FeatureCounts from Subread 
package (Liao et al., 2014). Genes with Reads Per Kilobase of transcript per Million mapped 
reads (RPKM) values more than 0.1 were considered as being actively transcribed and 
proceeded to the analysis of Differential Gene Expression (DGE) (Mortazavi et al., 2008). 
DEseq2 was used to perform the analysis of DGE, where genes with raw read counts as input. 
The differentially expressed genes were identified by adjust P value for multiple testing using 
Benjamini-Hochberg correction with False Discovery Rate (FDR) values less than 0.2.  
For Gene set enrichment analysis (GSEA), the read counts were first normalized by 
the Trimmed mean of M-values normalization method (TMM) (Robinson and Oshlack, 
2010), and then the normalized read counts were performed on the GESA platform from 
Broad Institute (http://www.broadinstitute.org/gsea/index.jsp). The analyses were based on 
gene ontology (c5.all.v2.5.symbols.gmt), BioCarta (c2.biocarta.v2.5.symbols.gmt) and 
KEGG (c2.kegg.v2.5.symbols.gmt). Gene sets with a nominal P value < .05 and FDR < .25 
were considered to be significantly enriched. All major computations were performed on 
resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced 
Computational Science (UPPMAX) under Project b2014299. 
3.11 Histology analysis 
Histology study provides direct observations of pathogenic tissues. In attached paper I and II, 
to confirm the pathogenic alterations in the mice, we performed histology analysis on 
different tissues, such as peripheral blood, bone, spleen, and liver. Blood smear and cytospin 
slides were stained by May-Grünwald-Giemsa. Soft tissue were embedded in paraffin after 
fixation and dehydration. However, bones contained abundant of calcium and were 
decalcified with EDTA before being embedded in paraffin for section. Hematoxylin and 
eosin (HE) staining is the basic staining method for identification of pathogenesis alterations 
in tissue sections. Hematoxylin mainly stains the anion nuclei in the cells with blue color, 
whereas eosin is an acid dye and stained cytoplasm or connective tissue with pink red 
appearance. The 3D Histech Slide Scanner is used for scanning the HE stained bone sections. 
Pannoramic Viewer (3D HISTECH) is used for taking the images of blood, BM, and spleen 
sections. In addition, megakaryocytes are big in size and can be easily recognized from the 
tissue image. Therefore, we further calculate megakaryocytes numbers per area with the help 
from the software of Pannoramic Viewer. 
3.12 Micro-Computed Tomography (µCT) 
Micro CT can generate 3D structures of different tissues from live animals through X-ray 
beam, and provide direct morphologies of tissues without invasion. Given different organ 
densities, µCT form a distinct contrast between bones and surrounding soft tissues, which 
helps to understand the alterations of bone mass during pathogenesis. In addition, the 
microstructures of bones, such as bone volume, bone marrow volume, trabecular number, 
trabecular thickness can be further quantified by using the software Analyze 12.0. Therefore, 
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in paper I, we performed µCT to observe the alterations of mouse bones between control and 
experiment mice and quantified the alterations.  
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4 Results and Discussions 
The thesis focuses on the roles of BM microenvironment on hematopoiesis and potential 
contributions of BM niche to myeloid malignancies. In study I, we determined that the Sipa1 
loss-induced MPN was driven by the abnormal BM niche, providing an evidence of BM 
niche-induced myeloid malignancy using the Sipa1-/- mouse model. Next, in study II, we 
investigated the roles of BM niche in the AML development induced by MLL-AF9+ AML 
cells, and revealed that native BM MSPCs inhibited the AML progression but could be 
educated to form a leukemia niche favoring the AML growth. These two studies presented 
the important roles of BM stromal cells in the MPN and AML in vivo. Meanwhile, we also 
studied the effects of different culture conditions on the characteristics of BM MSCs in vitro. 
As indicated in study III, we showed that SCA1 expression on BM MSCs was reduced under 
non-adherent culture condition compared to adherent cultivation. In addition, in contract to 
the previous finding using liquid culture, the 5-LO inhibitors failed to exert significant 
inhibition of the growth of CML patient LSCs in long-term culture-initiating cell (LTC-IC) 
experiment, suggesting a possible protection of CML cells by stromal cells from the 
inhibitors as shown in study IV.  
4.1 BM niche were altered in myeloid malignancies 
In study I and II, by taking advantages of Sipa1-/- MPN mouse model, MLL-AF9+ AML 
mouse model, and AML NGS xenograft model, we investigated the alterations of BM niche 
in these myeloid malignancies.  
To evaluate the involvement of BM niche in the progression of the MPN and AML, 
we phenotypically and functionally analyzed the BM niche cellular components in the mice 
when they developed to leukemia. In study I, the aged Sipa1-/- mice exhibited increased 
myeloid cells, enlarged spleens, BM megakaryocyte dysplasia, and leukocyte infiltration in 
their BM, indicating a mouse MPN phenotype of abnormal hematopoiesis. In these aged 
Sipa1-/- MPN mice, we detected increased BM MPCs but decreased MSCs, indicating altered 
BM cellular niche components in the MPN mice. In vitro multi-lineage differentiation assay 
implied increased adipogenic but declined osteogenic differentiation capicapies of the MSCs 
from aged Sipa1-/- MPN mice. These results indicated that BM stromal cells were 
phenotypically and functionally altered in the aged Sipa1-/- mice when they developed MPN. 
In study II, the AML mice displayed life threatening symptoms along with dramatic 
increased myeloid cells in blood and splenomegaly about 27-30 days after transplantation. 
We found that both frequencies and absolute numbers of BM MSCs, MPCs, and endothelial 
cells were increased in the AML mice. In vitro CFU-F assay of total BM mononuclear cells 
further confirmed the increased BM MSC numbers. To further understand the functional 
alterations of the AML BM MSCs, we performed in vitro multi-lineage differentiation assays, 
where we detected enhanced adipogenic and osteogenic differentiation capacities of AML 
BM MSCs. These results indicated that the AML BM stromal cells were phenotypically and 
functionally altered after the mice developed symptomatic AML. To dynamically monitor the 
alterations of the BM stromal cells, we analyzed the AML mice at different time point after 
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transplantation of AML cells. Interestingly, the phenotype of AML BM stromal cells seemed 
like normal at early stage after AML cell transplantation, but displayed alterations around 10 
days before they showed AML symptoms. Furthermore, the dynamic alterations of AML BM 
stromal cells exhibited a liner correlation with the AML engraftment in the mice. 
Accordantly, we also detected similar phenotypic alterations of patient AML cells in NSG 
mice, suggesting that primary AML cells from patients induced similar alterations to their 
BM niche. Together, these results indicated phenotypic and functional alterations of the BM 
niche in the mice with myeloid malignancies.  
4.2 The BM niche alterations in the Sipa1-/- mice prior to the MPN development 
In study I, given the alterations of both BM hematopoietic cells and the stromal cells in the 
aged Sipa1-/- mice with MPN, we wondered whether the alterations of the BM stromal cells 
were attributed to the intrinsic Sipa1 loss in the BM niche or the remodeling by malignant 
hematopoietic cells. To address this question, we characterized the BM niche of 3-month old 
young Sipa1-/- mice before the initiation of MPN. Interestingly, we detected increased BM 
MSCs and MPCs in the young Sipa1-/- mice although the hematopoietic cells were still 
normal. In vitro multi-lineage differentiation assay presented increased adipogenic but 
declined osteogenic differentiation capacities of the MSCs from the young Sipa1-/- mice, 
which were similar to that from the aged Sipa1-/- MPN mice. Furthermore, in vitro LSK 
HSPCs co-cultured with freshly sorted BM stromal cells from Sipa1-/- and Sipa1+/+ mice 
displayed an enhanced capacity of the Sipa1-/- MSCs and MPCs in promoting myeloid cell 
differentiation. These data indicated that the BM niche of young Sipa1-/- mice altered before 
the onset of MPN, which was probably due to the intrinsic loss of Sipa1 in BM niche, which 
might further led to MPN with time. 
4.3 Dysfunctional BM niche resulted in the MDS/MPN 
Previous study reported that SIPA1 expressed in mouse HSPCs (Ishida et al., 2003). 
Therefore, in study I, we designed transplantation experiments to determine whether Sipa1 
deficiency in the hematopoietic cells or BM niche led to the development of the MDS/MPN. 
We first transplanted CD45 beads enriched CD45.2+ cells from young Sipa1-/- mice, where 
the hematopoiesis remained normal, to 8-10 week old CD45.1+ Sipa1+/+ recipient mice which 
received lethally irradiation (9.5 Gy). However, we did not detect any abnormal 
hematopoiesis in the recipient mice, indicating that the Sipa1-/- hematopoietic cells from 
young adult mice alone could not induce the MPN in a normal BM niche. We next 
transplanted CD45 beads enriched CD45.1+ cells from Sipa1+/+ mice to CD45.2+ young 
Sipa1-/- mice and age-matched Sipa1+/+ mice under sublethally irradiation (6 Gy). Expectedly, 
in the Sipa1-/- recipients, we detected increased donor-derived myeloid cells in the PB and 
BM, increased donor-derived GMPs and MEPs in BM, and increased donor-derived CMPs 
and GMPs in the spleen. Although sublethally irradiation could not completely clear up 
endogenous hematopoietic cells of the recipient mice, but the leftover endogenous-derived 
myeloid cells did not present any difference between Sipa1+/+ and Sipa1-/- recipients. In 
addition, similar transplantations were performed on lethally irradiated Sipa1+/+ and Sipa1-/- 
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recipients. We observed even more severe phenotype of the MDS/MPN in the Sipa1-/- 
recipients, presenting reduced survival, increased myeloid cells in PB, BM hypercellularity 
and megakaryocyte hyperplasia, increased BM MEPs, splenomegaly, and increased HSPCs 
in spleen. The spleen cells from the primary Sipa1-/- recipients were then transplanted to the 
sublethally irradiated secondary Sipa1+/+ recipients, which exhibited MDS-like phenotype at 6 
month after transplantation. These results suggested that Sipa1-/- BM niche could induce the 
MDS/MPN in the mice. 
4.4 Suppressive roles of native BM MSCs in AML development 
BM Ebf2 expressing stromal cells have been identified as enriched MSC population with 
CFU-Fs with a frequency of 1 in 6 (Qian et al., 2013). In study II, to evaluate roles of Ebf2+ 
cells in the AML development, we first utilized an Ebf2-reporter mouse model (Ebf2-Egfp 
mice) as the recipient for AML transplantation. We next took the advantage of triple 
transgenic Ebf2-Egfp x Ebf2-CreER x Rosa 26-loxpStoploxp-Tomato mice to determine Ebf2+ 
cells-derived progeny during the AML development. Interestingly, we found that both Ebf2+ 
cells and Ebf2+ cells-derived progeny were increased in the MLL-AF9+ AML mice, and 
Ebf2+ cells could give rise to all fractions of BM stromal cells, indicating that Ebf2+ cells 
might be a key niche element contributing to the remodeling of BM niche during AML 
development. To functional test our hypothesis regarding the critical roles of Ebf2+ cells in 
AML development, we utilized transgenic Ebf2-CreER x Rosa26-loxpStoploxp-Dta mice as the 
recipients for establishing AML model. Surprisingly, we observed an overall shorter survival 
of the AML mice with the depletion of Ebf2+ cells. All together, our data suggested that 
Ebf2+ cells were critical BM cellular niche components and might act as a suppressor for the 
AML development. 
4.5 Deregulation of HSC niche factors in the development of myeloid malignancies 
Here we showed that myeloid malignancies could be induced from both abnormal BM niche 
(study I) and malignant hematopoietic cells (study II). We next investigated how the BM 
niche contributed to the leukemia.  
In study I, to further understand the underlying molecular mechanisms of the Sipa1-/- 
BM niche-driven MDS/MPN, we performed RNA sequencing analysis on freshly sorted BM 
MSCs, MPCs, and endothelial cells of young adult Sipa1+/+ and Sipa1-/- mice. Gene set 
enrichment analysis of the Sipa1-/- MSCs and endothelial cells exhibited up-regulated Ras and 
Rap1 signaling due to Sipa1 deficiency. Pro-inflammatory cytokines, such as TGF-β and 
IL6/JAK/STAT3 signaling, were increased in the Sipa1-/- MSCs, whereas TGF-β and TNFα 
signaling were enriched in the Sipa1-/- endothelial cells, indicating inflammation mediated 
MDS/MPN in the Sipa1-/- mice. Furthermore, Cxcl12, Kitl, and Angptl1 genes, which were 
critical for maintaining normal hematopoiesis, were reduced in the Sipa1-/- MSCs and MPCs, 
indicating impaired hematopoietic supportive functions of the Sipa1-/- BM niche. Il7, a 
lymphokine, was detected a reduction in the Sipa1-/- MPCs, indicating impaired 
lymphogenesis in the Sipa1-/- mice. Reduced Dicer1 expression, which could led to MDS in 
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mice (Raaijmakers et al., 2010), was also found in the Sipa1-/- MPCs. Reduced Runx2 in the 
Sipa1-/- MSCs and MPCs implied an impaired osteogenic differentiation capacity, which 
further confirmed the declined osteoblast differentiation of the Sipa1-/- MSCs in vitro. In 
addition, Thpo, which was critical for HSC maintenance (Qian et al., 2007), was increased in 
the Sipa1-/- MPCs, and the increased THPO protein was further confirmed in BM plasma in 
the Sipa1-/- mice, indicating an altered THPO signaling in the Sipa1-/- MPCs.  
In study II, to understand the underlying molecular mechanisms of BM niche to 
AML progression, we studied the gene expressions on freshly sorted BM stromal cells after 
the mice developed symptomatic AML. The BM MPCs have been shown as the main sources 
for the productions of cytokines and growth factors in the BM niche (Mendez-Ferrer et al., 
2010). The BM MPCs of the AML mice were detected with impaired hematopoietic 
maintenance gene expressions, such as Cxcl12, Kitl, and Angptl1. Furthermore, the AML 
MPCs exhibited a decline of Il7 and Col1a1 expression, but an increase of Spp1/Opn, Il6, 
Lama4, and Jag1 expression. In addition, the AML MSCs showed a reduction of Angptl1 and 
Col1a1 expression, but an increase of Lama4, Lama5, Il6, and Fabp4 expression; while AML 
endothelial cells presented an increase of Tgfb1 and Lama5 expression. These results 
indicated that inflammatory cytokines (such as Il6, Spp1 and Tgfb1), matrix proteins (such as 
Lama4, Lama5, and Col1a1), Notch signaling (Jag1), and hematopoietic maintenance growth 
factors (such as Cxcl12, Kitl, and Angptl1) from the BM niche were involved in the AML 
progression. The dynamic gene expression assay further revealed that most of the gene 
alterations were correlated with AML burden, and indicated that early interventions of these 
gene expressions might affect AML progression. 
Abnormal BM niche-induced MDS/MPN and leukemic cells-induced AML indicated 
different origin of myeloid malignancies. However, from the gene expression profiles, we 
found that the hematopoietic maintenance growth factors including Cxcl12, Kitl, and Angptl1 
were declined whereas inflammatory cytokine signaling were increased in the altered BM 
niche cells of the two leukemic mouse models. These results indicated that targeting on BM 
niche cells or niche factors might provide new treatments for MDS/MPN and AML. 
4.6 Phenotype alteration in BM MSCs in culture 
MSCs have been shown to change their phenotypes under different microenvironment (Qian 
et al., 2012; Tormin et al., 2011). SCA1 has been identified as a mouse MSC marker 
expressed on both freshly isolated MSCs and cultured MSCs. In study III, we characterized 
the SCA1 expression of mouse BM MSCs under adherent and non-adherent cultures, and 
detected a reduction of the SCA1 expression on the MSCs under non-adherent culture for 72 
hours compared to that in adherent cultivation. In addition, the MSCs from non-adherent 
culture regained the SCA1 expression after being reseeded into adherent plastic culture for 5 
days, indicating non-adherent culture could temperately down-regulate the SCA1 expression 
on MSCs. This study provided another evidence of culture-related phenotypic alteration of 
MSCs.  
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4.7 Possible protection of LSCs by stromal cells from pharmaceutical therapy 
ALOX5 inhibitors have been applied to a clinic trial based on the promising results from the 
CML mouse experiments, where the application of ALOX5 inhibitor impaired the mouse 
CML stem cells and prolonged the survival of the CML mice (Chen et al., 2009). In study IV, 
we examined the expressions of leukotriene signaling molecules of CML leukemic stem and 
progenitor cells and evaluated their survival using pharmaceutical inhibitors targeting 
ALOX5 or cysteinyl leukotriene receptor 1 in vitro. However, the ALOX5 inhibitors failed to 
exert significant inhibition of the growth of CML patient LSCs in LTC-IC experiment. In 
contract to the previous study that CML cells were inhibited in liquid culture, our study 
suggested a possible protection of CML cells by stromal cells from the inhibitors in vitro. 
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5 Concluding Remarks 
This thesis has phenotypically, functionally and molecularly demonstrated the altered BM 
niche and their involvements in the development of myeloid malignancies. By using mouse 
models, paper I and II provided evidence for distinct roles of BM niche in initiation and 
progression of myeloid disease. In paper I, we demonstrated that the loss of Sipa1 in mice led 
to BM niche alterations before the onset of MDS/MPN, and confirmed that the loss of Sipa1 
in the BM niche, but not in the hematopoietic cells resulted in the MDS/MPN. In paper II, we 
determined that native BM niche suppress the AML development, but could be gradually 
altered by leukemic cells favoring the AML growth. These two studies revealed the 
underlying mechanisms of the impaired BM niche-induced MDS/MPN and the AML-
educated BM niche with self-reinforcing loops. Additionally, paper III illustrated that non-
adherent culture could reduce the SCA1 expression of mouse BM MSCs. Finally, by single 
cell assays of CML LSCs, our study (paper IV) suggested that targeting leukotriene signaling 
ALOX5 and CYSLT1 with leukotriene antagonists was not helpful for suppressing CML 
growth in LTC-IC assay. 
Collectively, we phenotypically, molecularly, and functionally characterized 
leukemic BM niche and determined the niche alterations and contributions to different 
myeloid malignancies. In addition, we revealed the underlying mechanisms of BM niche-
induced MDS/MPN in mice, BM niche involvement in AML development in vivo, and 
potential protection of CML cells in culture. Targeting BM niche factors or restoring BM 
niche components might be new therapeutic strategies for these myeloid malignancies. 
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